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ABSTRACT 
 
Plasmodium vivax Duffy binding protein (DBP) is an essential ligand for 
reticulocyte invasion making it a premier asexual blood stage vaccine candidate. 
However, strain-specific immunity due to DBPII allelic variation may complicate 
vaccine efficacy, suggesting that an effective DBPII vaccine needs to target 
immune responses to conserved epitopes that are potential targets of strain-
transcending neutralizing immunity. Anti DBPII monoclonal antibodies, which 
were previously characterized by COS7 cell binding assay as inhibitory and non-
inhibitory to DBPII-erythrocyte binding, were mapped to DBPII gene fragment 
libraries using phage display. Inhibitory mAb 3C9 binds to a conserved 
conformation-dependent epitope in subdomain 3 while non-inhibitory mAb 3D10 
binds to a linear epitope in subdomain 1 of DBPII.  
More definitive epitope mapping of mAb 3D10 was achieved using a 
random peptide library displayed on phage. Since DBP region II is mostly made 
up of alpha-helices, we used a randomized helical scaffold library, the Affibody 
library, displayed on phage, to determine epitope of conformation-dependent 
antibodies.  
The immunogenicity of the identified epitopes was evaluated in mice and 
the immune sera evaluated for binding to DBPII by ELISA and inhibition of DBPII-
erythrocyte binding by the COS7 cell assay. Immune serum from the mAb3C9 
	   vii 
epitope blocked DBPII-erythrocyte, suggesting this epitope could be a good 
subunit vaccine target.
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CHAPTER ONE: 
INTRODUCTION 
 
WORLDWIDE MALARIA 
Malaria, a preventable and curable infectious disease, has plagued 
mankind for the centuries and is cumulatively the deadliest disease. The 
unmistakable overlap of the prevalence of malaria with certain human 
erythrocytic polymorphisms, hemaglobinopathies, enzymopathies and 
immunogenetic variants are visible marks of the patterns of selection, where the 
homozygote's disadvantage (if any) is balanced by the attenuated virulence of 
the malaria parasite to the heterozygote host (Haldane, 1949). The phylum 
Apicomplexa of the obligate intracellular parasite, Plasmodium, is known for its 
flagship apical organelles (rhoptries, micronemes and dense granules) seen in 
the invasive stage. Most species in this phylum simultaneously use three distinct 
genomes; housed in the nucleus, mitochondrion and apicoplast (a non-
photosynthetic chloroplast remnant) enabling a complex life cycle as it 
effortlessly invades and takes over a myriad of sundry cells. Quinine followed by 
Chloroquine, a less toxic derivative, was the drug of choice until resistance was 
seen in the 1960’s. Artemisinin in combination with at least one other drug is the 
accepted treatment today to prevent speedy development of drug resistance by 
the parasite.     
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In humans, malaria is caused by P. falciparum, P. vivax, P. malariae, P. 
ovale and P. knowlesi; and spread by 70 sub-species of the female Anopheles 
mosquito. An estimated 198 million cases of malaria and 584,000 deaths were 
left in its wake in 2013. Although the true global burden of the disease is 
unknown, due to wide-spread under-reporting, globally, 3.3 billion people, are at 
risk of being infected ("World Malaria Report 2014," 2014) 
 
Malaria caused by P. vivax 
Plasmodium vivax has the widest geographical distribution and is a major 
cause of morbidity (Gething et al., 2012). Although vivax malaria is historically 
called ‘benign tertian malaria’, when trying to eliminate malaria it is often the ‘last 
parasite standing’ (Garnham, 1951; Tatem et al., 2010).  
During the acute vivax malaria stage, paroxysms are accompanied with 
headache (87%), cough (42%), muscle pain (35%), nausea (29%), vomiting 
(24.5%), abdominal pain (25%), diarrhea (4%), clinical anemia (5%), a palpable 
spleen (8%) and palpable liver (3%) (Luxemburger et al., 1998). In recent years 
there has been an increase in the number of cases of severe and fatal vivax 
malaria in both children and adults particularly with severe anemia and low birth 
weight (Genton et al., 2008; Kochar et al., 2005; Lacerda et al., 2012; Rijken et 
al., 2012; Tjitra et al., 2008). Strains with low sensitivity to primaquine (the only 
drug to prevent relapse) are also increasing (Baird & Hoffman, 2004) along with 
widespread resistance to existing antimalarial drugs (Mohan & Maithani, 2010; 
Rijken et al., 2011).  
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Plasmodium vivax preferentially invades reticulocytes (Butcher, Mitchell, & 
Cohen, 1973; Mons, 1990) with Duffy blood group antigen otherwise known as 
Duffy antigen receptor for chemokines (DARC) (Miller, Mason, Clyde, & 
McGinniss, 1976). DARC, a receptor on the surface of red blood cells (RBCs), is 
encoded by the Fy gene with codominant alleles FY*A and FY*B. A point 
mutation at the binding site of the transcriptional factor GATA-1 in the Duffy gene 
promoter renders the phenotype Duffy antigen negative erythrocytes 
(Tournamille, Colin, Cartron, & Le Van Kim, 1995). Interestingly, though the 
GATA-1 mutation appears on both alleles, Duffy negative Africans are more likely 
to have FY*B while a Duffy negative South East Asian would have FY*A 
(Zimmerman et al., 1999). The Fy(a)/Fy(b) phenotype is defined by a nucleotide 
transition, giving Gly(Fya) or Asp(Fyb) at position 42 in the extracellular amino-
terminal domain (Tournamille, Le Van Kim, Gane, Cartron, & Colin, 1995). FY*A 
allele seems to confer some degree of resistance to vivax malaria as compared 
to FY*B as antibodies that are either naturally acquired or artificially induced 
block rPvDBPII from binding to Fy(a) erythrocyte better than to Fy(b) erythrocytes 
(Chittoria, Mohanty, Jaiswal, & Das, 2012; King et al., 2011; Maestre et al., 2010; 
Souza-Silva et al., 2014). 
 
MALARIA LIFE CYCLE 
Although symptoms of malaria have been described in Chinese literature 
dating back to 2700 BC, it was not until 1880 that Charles Louis Alphonse 
Laveran “follow(ed) the pigment” and disproved the theory of the day that malaria 
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was caused by a bacterium. He noticed the parasitic protozoan in the blood of 
patients with malaria and that quinine treated them. By 1897, Patrick Manson 
and Ronald Ross working together to “follow the flagellum” (in reference to the 
male gamete) demonstrated that malaria parasites could be transmitted from 
infected patients to mosquitoes which were identified as the definite host.  
The life cycle of Plasmodium starts with an infected female Anopheles 
mosquito that bites a human for a blood meal and transmits a few sporozoites 
from its saliva. These sporozoites invoke an antibody response to sporozoites 
proteins. Following the infectious bite, MacCallum (1898) showed that the 
parasite travels through the blood to the liver where it develops silently 
undergoing clonal expansion for the first 10 days or so in the liver. This is the 
exoerythrocytic stage. Within the liver, these sporozoites grow and undergo 
several rounds of mitotic division to release tens of thousand merozoites. These 
merozoites seem to act as a ‘stealth shuttle’ (Alan F. Cowman & Kappe, 2006) as 
it dodges phagocytes like Küpffer cells and dendritic cells  and makes its way into 
the bloodstream. In P. vivax, sporozoites can differentiate into a dormant stage 
called a hypnozoite that, upon activation after months or years, causes clinical 
relapse (Krotoski, 1985). Cell-mediated T-cell response is the most important 
immune response, destroying infected hepatocytes.   
The released merozoites then invade erythrocytes initiating the pathogenic 
erythrocytic stage. Inside the erythrocyte, the merozoite grows from a ring form to 
a trophozoite, which remains uninucleated. The trophozoite’s nucleus divides 
asexually to form schizonts, which further divide to form mononeucleated 
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merozoites. When the merozoites are mature, the erythrocyte ruptures releasing 
approximately 20 merozoites and some parasitic waste (toxins). These released 
merozoites invade new erythrocytes and the cycle of replication and rupture 
continues, bringing about the characteristic fever and chills cycle of the disease. 
Fever also occurs 2 – 3 days before parasite load is high enough to be detected 
in blood. P. vivax has a lower pyrogenic threshold than P. falciparum. Under drug 
pressure, sometimes P. falciparum ring-stages can become dormant and hide in 
the RBCs until conditions for replication becomes more favorable, although it is 
uncertain if the same phenomenon occurs for P. vivax. Naturally acquired 
immunity (NAI) is mainly associated with the blood stage of the disease with the 
production of antibodies specific to the merozoite proteins. Occasionally, once 
immunity to blood-stage is acquired, infections can fall to below limits detectable 
by standard microscopic methods, but parasite-infected blood cells are not 
completely cleared. When these infections re-emerge to a detectable level, even 
causing a clinical episode, it is called recrudescence.  These infections are 
distinct from relapse infections, which are initiated by new merozoites emerging 
from dormant liver stage parasites.   
Some merozoites form male or female gametocytes that do not rupture 
erythrocytes. In P. vivax, gametocytes develop in 56 hours after infecting a 
reticulocyte and can be seen in the blood before the onset of clinical symptoms. 
When a female anopheline mosquito feeds on an infected human, it ingests the 
parasites in the blood, beginning the sporogonic cycle. In the mosquito, 
gametocytes develop into male and female gametes capable of forming a zygote. 
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The zygote becomes a motile and elongated oökinate that invades the 
mosquito’s midgut wall forming an oocyst. Over several days an oocyst 
undergoes 10-11 rounds of mitosis to form a syncytial cell sporoblast that will 
release thousands of sporozoites. These sporozoites then migrate to the salivary 
gland ready to continue the cycle when the mosquito takes its next blood meal. 
Thus the parasite undergoes more than ten stages of cellular differentiation and 
invades at least four types of cells within two different hosts. 
 
Immune response to malaria 
Historically, malaria immune naïve humans were protected or had a mild 
form of the disease after adoptive transfer of serum from an infected human 
(Cohen, Mc, & Carrington, 1961; McGregor, 1964). In the mid 1960s, 
experiments on neurosyphilitic patients immune naïve to malaria, proved that 
immunity to malaria is species and strain specific (Jeffery, 1966). Increased 
frequencies of CD4+ T cells and memory CD4+ T cells have been correlated with 
protection from P. falciparum and P. vivax infection in humans, respectively 
(Jangpatarapongsa et al., 2006; Reece et al., 2004).  T cells help produce high 
affinity antigen specific B cells, regulate inflammatory response and activate 
natural killer (NK) cells and monocytes. High affinity inhibitory antibodies and 
memory T cells targeting critical regions of molecules may both be essential for 
an effective immune response (Mueller et al., 2013). 
The first humoral response is against sporozoites proteins like 
circumsporozoite protein (CSP) and thrombospondin related anonymous protein 
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(TRAP) (Cerami, Kwakye-Berko, & Nussenzweig, 1992; Hedstrom et al., 1990; 
Sultan et al., 1997; Vanderberg, Nussenzweig, & Most, 1969). Several pre-
erythrocytic antigen specific CD4+ and CD8+ T cell epitopes have been identified 
(Cockburn et al., 2010; Joshi, Bharadwaj, Chatterjee, & Chauhan, 2000; 
Overstreet, Cockburn, Chen, & Zavala, 2008).  
Antibodies to merozoite proteins and ligands that are critical for junction 
formation and invasion play a crucial role in preventing merozoite invasion of 
RBC. In P. falciparum antigenic variation and cytoadherence of infected RBCs, 
caused by approximately 60 var genes expressed one at a time that encode for 
erythrocyte membrane protein 1 (PfEMP1), is a key contributor to complicated 
malaria (Biggs et al., 1991; Roberts et al., 1992; Scherf et al., 1998). While 
sequestration enables the parasite to avoid spleen-dependent killing, antigenic 
switching is a challenge for antibody production. P. vivax does not have var 
genes and because of the flexibility of its host cell it does not need to sequester. 
Antibodies also enhance phagocytic activity of monocytes and macrophages.  
During the acute phase of the disease, a strong Th1 pro-inflammatory 
response is typical for malaria with the production of inflammatory cytokines and 
chemokines like tumor necrosis factor (TNF)-alpha, IFN-gamma, IL-1, IL-6, and 
IL-12 to help prevent hyperparasitemia (Ockenhouse et al., 2006). Although 
inflammatory cytokines help clear parasitemia, it can cause severe disease due 
to endothelial dysfunction, sequestration and anemia. Hepcidin, the iron 
regulatory hormone secreted from macrophages and hepatocytes, is up-
regulated in the presence of pro-inflammatory cytokines and may play a key role 
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in anemia related complications of P. falciparum infection (Nemeth et al., 2004; 
Nweneka, Doherty, Cox, & Prentice, 2010). However, a strong regulatory 
response determined by plasma IL-10 levels, have been found to be more 
elevated in P. vivax compared to P. falciparum infection (Goncalves, Scopel, 
Bastos, & Ferreira, 2012; Han et al., 2010). Antigen-specific CD4+ T cell 
expansion is inversely regulated by increase in CD4+(FoxP3+) natural regulatory 
T cells (Jangpatarapongsa et al., 2008). CD4+ T cells in turn activate NK and 
ϒδT cells (Artavanis-Tsakonas et al., 2003; D'Ombrain et al., 2008), which are 
thought to act as a bridge between innate and acquired immunity.  
Naturally acquired immunity (NAI), first described by Robert Koch in 1899, 
is the collective parasitological and clinical immune response to second and 
subsequent infections. NAI is largely associated with antibody response to blood 
stage infection but can also result in reduction of transmission of gametes to the 
mosquito or interfere with development of gametes in mosquito. NAI is 
considered to be cumulatively dependent on exposure to multiple parasitic 
infections (premunition), is relatively species and strain specific, and is 
modulated by age at first exposure. NAI to P. vivax is manifested as protection 
against high-density parasitemia and uncomplicated malaria at a younger age as 
compared to P. falciparum (Mueller et al., 2009). Unlike NAI to P. falciparum, 
immune naïve adults do no acquire clinical immunity with relatively few 
exposures than children (Baird, Jones, et al., 1991; Baird et al., 2003). NAI is one 
of the main rationales behind pursuing a multivalent blood stage vaccine. 
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MALARIA VACCINES 
Vaccination is historically the most effective way to prevent infectious 
diseases but the malaria parasite is considerably more complex than bacteria 
and viruses that most vaccines target. With over 5000 genes the malaria parasite 
is very good at evading the immune system as it uses multiple pathways to 
invade host cells with polymorphic stage specific ligands. Hence developing a 
vaccine against malaria has intrigued scientists globally across time. The first 
success made towards development of a vaccine for malaria was in 1967 using 
radiation attenuated sporozoites to protect against infection with malaria in mice 
(Nussenzweig, Vanderberg, Most, & Orton, 1967). Today the RTS,S a pre-
erythrocytic, P. falciparum subunit vaccine of the repeat region and Tc epitope of 
a CSP, is the only vaccine candidate that has under gone phase 3 clinical trials. 
As the efficacy of the vaccine varied greatly with transmission intensity (Bejon et 
al., 2013) the need for a more efficacious second-generation anti-infection 
vaccine (against pre-erythrocytic stage) and anti-disease vaccine (against 
asexual blood stage) is still very urgent. In addition, transmission-blocking 
vaccines that target pre-erythrocytic and/or sexual sporogonic stage is also being 
studied. Phase I clinical trials for vaccine candidates against P. vivax pre-
erythrocytic stage and for transmission blocking have been carried out (reviewed 
in (Reyes-Sandoval & Bachmann, 2013). However, none of the blood stage 
vaccine candidates have reached that mile-marker.  
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P. vivax asexual blood stage vaccines  
Plasmodium vivax merozoite proteins that have a role in reticulocyte 
invasion and can elicit a significant NAI are being studied such as the apical 
membrane antigen-1 (PvAMA1), merozoite surface proteins (PvMSPs), 
reticulocyte binding proteins (PvRBPs) and Duffy binding protein (PvDBP). All of 
these proteins except for PvMSPs have highly polymorphic immunodominant 
regions that are suggestive of immune pressure.  PvMSP1 and PvDBP have 
been studied the most. 
Though PvRBPs are among the first apically located protein to bind 
irreversibly to reticulocytes (Galinski & Barnwell, 1996; Galinski, Medina, 
Ingravallo, & Barnwell, 1992), triggering the release of PvDBP from the 
mironemes for junction formation (Singh et al., 2005), very few studies have been 
done to understand NAI to PvRBPs. One study in Brazil showed antibodies 
correlated significantly to exposure and were directed towards the N-terminal 
polymorphic putative binding region (Tran et al., 2005).   
The apical membrane protein1 is localized in the microneme and AMA1 
interacts with rhoptry neck protein-2 (RON2) to form the moving junction complex 
during merozoite invasion (Srinivasan et al., 2011).  PvAMA1 is pro-inflammatory 
and produces an IgG1 and IgG3 response (Wickramarachchi et al., 2006). 
Immune response had been detected to linear and conformational epitopes of 
the polymorphic Domain II and specifically the conserved loop region (Chesne-
Seck et al., 2005; Lal et al., 1996; Pizarro et al., 2005).  
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The merozoite surface proteins family has several potential vaccine 
candidates; PvMSP-1 fragments, PvMSP-3 family (PvMSP-3.1, PvMSP-3.3 and 
PvMSP-3.10) PvMSP-4, PvMSP-5 and PvRBP-5 1/2 and PvMSP-9. PvMSP1 is 
the most abundant blood stage antigen that undergoes two successive 
proteolytic cleavages to form MSP142 and then MSP119 (Blackman, Scott-
Finnigan, Shai, & Holder, 1994) . Although MSP1 shows humoral and cellular 
reactivity; and human antibodies to MSP1 correlated with protection against P. 
vivax infection, yet vaccination of non-human primates with MSP119 failed to 
consistently induce antibody production (Valderrama-Aguirre et al., 2005). Of the 
11-member msp3 gene family, B cell epitopes to PvMSP3.10’s α-helical region 
has been reported with a predominance of IgG1 antibodies followed by IgG2 
(Lima-Junior et al., 2011). Antibody response to PvMSP9 is high among 
individuals that carry HLA-DRB1*04 (Lima-Junior et al., 2010). IgG1 and IgG2 
response is correlated with age, IFN-γ and IL-4 responses were also generated 
to the peptide (Lima-Junior et al., 2008).  
 
The Duffy Binding Protein 
Specific receptor ligand interactions are required for the malaria parasite 
to invade erythrocytes. The Duffy binding protein (DBP) was first identified in the 
model parasite P. knowlesi (PkDBP) (Adams et al., 1990; Haynes et al., 1988) 
and then in P. vivax (PvDBP) (Fang, Kaslow, Adams, & Miller, 1991; Wertheimer 
& Barnwell, 1989).  The approximately 140 kDa type I membrane DBP is 
sequestered in the micronemes and expressed during late schizont development 
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and then released on the surface of the merozoite at or around the time of 
invasion (Adams et al., 1990; Fang et al., 1991; Haynes et al., 1988; Wertheimer 
& Barnwell, 1989).  
Unlike P. falciparum, P. vivax merozoites almost exclusively use the Duffy (Fy) 
antigen receptor for chemokines (DARC) to invade erythrocytes (Miller et al., 
1976). DARC is a glycosylated membrane protein more abundant on the surface 
of reticulocytes than on mature erythrocytes and is also expressed on the 
endothelial surfaces of some organs. In vitro invasion studies using P. knowlesi 
demonstrated that initial interaction and apical reorientation can take place 
normally on most human erythrocytes, but junction does not develop and 
invasion does not progress to junction formation on Duffy-negative human 
erythrocytes (lack DARC) (Miller et al., 1976). More recently there have been few 
P. vivax cases among Duffy negative individuals (Cavasini et al., 2007; Menard 
et al., 2013; Ryan et al., 2006) however, these cases seem to be very rare and 
an alternate reticulocyte receptor and merozoite ligand has not yet been 
identified.  Hence DBP is the leading vaccine candidate. 
The invasion of erythrocytes by Plasmodium merozoites is a complex, 
multistep process involving an initial “long-distance” recognition of red blood cell 
surface receptors and attachment, after which a process of reorientation takes 
place to align the apical end to face the erythrocyte (Galinski & Barnwell, 1996; 
Srinivasan et al., 2011), a tight junction is then formed involving high-affinity 
ligand-receptor interactions. The junction is seen initially as a thickening of the 
erythrocyte membrane at its point of contact with the merozoite, which then 
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transforms into a ring that moves around the merozoite, powered by the 
parasite's actin-myosin motor shedding the surface coat in the process. Upon 
reaching the posterior pole, the adhesive proteins at the junction are also 
proteolytically removed, this time by a resident protease facilitating resealing of 
the membrane. When the invasion is complete, the merozoite finds itself in a 
vacuole surrounded by a vacuolar membrane called parasitophorous vacuole (A. 
F. Cowman & Crabb, 2006). 
Although this may not be the only mechanism for invasion of reticulocytes 
by P. vivax, PvDBP is the founding member of the family of Duffy-binding-like 
erythrocyte binding proteins (DBL-EBPs) (Adams et al., 1992) that includes P. 
falciparum EBA175, PfEBL1, P. knowlesi DBPα,β and γ among others (Adams, 
Blair, Kaneko, & Peterson, 2001). The Duffy-binding-like domain is characterized 
by two cysteine-rich regions (in PvDBP region II and region VI) and conserved 
exon-intron structures (Adams et al., 1992). 
Growing in vitro P. vivax cultures is a hurdle that is yet to be over come 
however, an in vitro functional assay, the COS7-binding assay, was developed to 
study binding of RBCs to transfecting COS7 cells expressing DBP on the surface 
of COS7 cells. Using the COS7-binding assay it was determined that the 
cysteine rich region II of DBP (DBPII) is critical for binding to DARC (Chitnis & 
Miller, 1994). However, PvDBPII is extremely polymorphic with a nucleotide 
substitution rate four times higher than the rest of the molecule (Ampudia, 
Patarroyo, Patarroyo, & Murillo, 1996; J. Cole-Tobian & King, 2003; Xainli, 
Adams, & King, 2000). Antibody responses to PvDBP are seen in people living in 
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P. vivax endemic areas and the elevated levels of amino acid sequence 
polymorphisms may be signs that the molecule is under selective pressure 
(Ampudia et al., 1996; J. L. Cole-Tobian et al., 2002; Fraser et al., 1997; P. A. 
Michon, Arevalo-Herrera, Fraser, Herrera, & Adams, 1998; Tsuboi et al., 1994).  
Using site directed mutagenesis, it was determined that polymorphic 
residues flanked residues critical for receptor binding suggesting variation in BC 
epitopes is consistent with an immune evasion mechanism (Hans et al., 2005; 
VanBuskirk, Sevova, & Adams, 2004). Additional studies confirmed that amino 
acid substitutions in some of the polymorphic residues alter sensitivity to anti-
DBP inhibitory antibodies (VanBuskirk, Cole-Tobian, et al., 2004). In 2011 the 
crystal structure of PvDBPII was determined and the structure corroborated 
previous studies indicating that polymorphic residues flanked residues critical for 
binding, on the surface of PvDBPII (Fig 1.6 A) (Batchelor, Zahm, & Tolia, 2011). 
Cumulatively, these results suggest that polymorphic residues act as a 
mechanism to misdirect the immune response away from the conserved residues 
critical for binding as PvDBPII haplotype-specific antibody response correlates 
with only homologous and not heterologous protection (Ceravolo et al., 2009; 
Chootong et al., 2010; J. L. Cole-Tobian et al., 2009; Grimberg et al., 2007; King 
et al., 2008; VanBuskirk, Cole-Tobian, et al., 2004; Xainli et al., 2002; Xainli et 
al., 2003).  
PvDBPII is largely alpha-helical and may be assigned into three sub-
domains delineated by six disulphide bonds. While sub-domain1 of PvDBPII is 
made up of an antiparallel beta-hairpin, sub-domains 2 & 3 seen as distinct 
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bundles of three alpha-helixes.	  	  NMR studies of PvDBPII in contact with the core 
region of DARC ectodomain revealed that dimerization of PvDBPII is required for 
and driven by receptor engagement as DARC ectodomain form a helix that binds 
to the dimer interphase (Fig 1.7 A) (Batchelor et al., 2014). In addition, the 
receptor DARC is sulfated at tyrosine residues 30 and 41, right next to residue 42 
that expresses the variant Fy(a)/Fy(b) phenotype, and sulfation of tyrosine 41 
has been shown to play a critical role in binding to PvDBP (Fig 1.7 B) (Batchelor 
et al., 2011; Choe et al., 2005). 
Although NAI to PvDBPII is present in P. vivax endemic areas, anti-DBPII 
immune response tends to increase with age and exposure (Chootong et al., 
2010; J. L. Cole-Tobian et al., 2002; Grimberg et al., 2007; VanBuskirk, Cole-
Tobian, et al., 2004; Xainli et al., 2003). Studies have shown that about 8-10% of 
P. vivax exposed individuals produce high titer strain-transcending broadly 
neutralizing antibodies (King et al., 2008), associated with 50% reduction in risk 
of infection with P. vivax (Chootong et al., 2010; King et al., 2008). Vaccine 
induced anti-DBP antibodies showed partial erythrocyte binding inhibition in 
COS7 assay (Devi et al., 2007) as well as partial inhibition of merozoite invasion 
of erythrocyte (Arevalo-Herrera et al., 2005). Vaccine induced anti-DBP 
antibodies also induced partial protection in monkeys (Arevalo-Herrera et al., 
2005). Crystal structure and site directed mutagenesis studies (Batchelor et al., 
2014; VanBuskirk, Sevova, et al., 2004) suggest that strain transcending 
neutralizing antibodies may be directed to the conserved dimer interface (Fig 1.6 
B) or may sterically inhibit dimerization.   
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In pre-clinical mouse studies, a multi-allele PvDBPII vaccine was more 
immunogenic and produced a stronger strain neutralizing response than a single-
allele vaccine (Ntumngia et al., 2013). To overcome the inherent tendency for 
anti-DBP immune responses to be strain specific, a novel synthetic PvDBPII 
called DEKnull was produced. The B-cell immunodominat and polymorphic 
residues of the DEK epitope (Chootong et al., 2010) were mutated in DEKnull. 
Compared to the natural parent allele Sal1, DEKnull vaccine was less 
immunogenic but it produced an immune response that was similar to a single 
natural allele vaccine (Ntumngia & Adams, 2012; Ntumngia et al., 2013). These 
studies prove that identifying epitope targets of broadly neutralizing inhibitory 
antibodies on DBP will be very helpful in designing a vaccine that produces 
strain-transcending immunity.  
 
PHAGE DISPLAY AND BIOPANNING 
In the mid 1980’s George Smith performed a series of seminal 
experiments that revolutionized protein engineering and the study of protein-
protein interactions. Smith demonstrated that a bacteriophage could express an 
exogenous protein by genetically encoding the gene (here, gene encoding EcoRI 
endonuclease) as a chimera to protein pIII on the surface of the phage, coining 
the term phage display (Smith, 1985). These findings meant that proteins could 
be easily produced in the right conformation and ready to use on the phage by 
cloning the specific gene into the phage genome; which bypassed the laborious 
method of producing, selecting, purifying and refolding protein produced within 
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bacteria. Smith further demonstrated both, that EcoRI-pIII protein chimera 
retained its ability to bind its specific antibody and that phage displaying the 
chimera could be selected from a mixture of wild-type phage by affinity 
enrichment using anti EcoRI antibodies (Smith, 1985). This method of affinity 
enrichment was termed biopanning (Parmley & Smith, 1988).   
  A bacteriophage (phage) is a virus that exclusively infects bacteria by 
attaching to specific bacterial cell wall phage receptors, including sex-pili, 
flagella, and cell wall lipoproteins, polysaccharides, and lipopolysaccharides. 
Following infection, the phage uses the host’s machinery to synthesize progeny 
thereby suppressing the host’s gene expression and metabolic activities. The 
lytic cycle of the phage usually culminates in the release of viral progeny and 
bacterial cell content into the medium (Neufeld, Mittelman, Buchner, & Rishpon, 
2005). 
The filamentous phage (Ff) M13, a single-stranded DNA phage that 
infects Escherichia coli strain that carries a F- conjugative plasmid, is the most 
commonly used phage display vector. Surface protein pIII and VIII have been 
used as chimeras with exogenous protein to be expressed. Major capsid protein 
VIII has been used to express small peptides in large numbers, to study avidity 
interactions, while minor capsid protein pIII can be used to display proteins to 
study affinity interactions (Iannolo, Minenkova, Petruzzelli, & Cesareni, 1995; 
Smith & Scott, 1993). Gene III protein displayed as 5 copies, at one tip of the 
virion, mediates adsorption to the host sex-pili. The C-terminus of the protein III 
remains anchored in the phage coat while the N-terminal is responsible for 
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binding to the F-pilus of the host. Peptides to be displayed are fused to the N-
terminal portion of the gene III protein. To maintain infectivity of the phage, a 
special vector system termed 3+3, was developed that included the wild type pIII 
gene in a helper phage and the recombinant gene on a phagemid (Bass, 
Greene, & Wells, 1990; Russel & Model, 1986).    
 Over the past three decades phage display has influenced many fields in 
the study of malaria like identifying novel protein-protein interactions, drug design 
and target validation, diagnostic and therapeutic antibody fragments, vaccine 
design and epitope mapping. These are briefly discussed below.  
A novel interaction between Erythrocyte binding antigen-181 (EBA-181) 
and human erythrocyte membrane protein 4.1 (4.1R) was identified using P. 
falciparum cDNA library biopanned against 4.1R (Lanzillotti & Coetzer, 2006; 
Sonja B. Lauterbach, Lanzillotti, & Coetzer, 2003). Novel interaction between the 
amino-terminus of MSP1 and RBC glycophorin A (GPA) suggesting an essential 
role of the MSP1-GPA-band 3 complex during the initial adhesion phase of 
malaria parasite invasion of RBCs (Baldwin, Li, Hanada, Liu, & Chishti, 2015). 
Novel mosquito midgut receptor, enolase-binding protein (EBP) that binds to 
oökinate surface ligand (enolase), is one of the two pathways used by the 
oökinates to invade the mosquito midgut. The mosquito EBP was identified when 
SM1, a 12-aa peptide mimotope of enolase, identified after 5 rounds of panning 
to salivary glands and mosquito midgut was studied (Ghosh, Ribolla, & Jacobs-
Lorena, 2001; Vega-Rodriguez et al., 2014). Identification of (novel) enzyme 
substrates and inhibitors like P. falciparum M18 aspartyl aminopeptidase 
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(PfM18AAP) interaction with the human erythrocyte membrane protein spectrin 
are being understood using phage display. PfM18AAP seems to have a 
multifunctional role that utilizes several substrates and digests hemoglobin (S. B. 
Lauterbach & Coetzer, 2008).  
Identifying a possible drug target; a 14-residue long disulfide-bonded 
peptide selected by phage display screen targeting the catalytic domain of P. 
falciparum serine repeat antigen 5 (SERA5) and delays egress in a dose-
dependent manner, demonstrating the potential of SERA5 to be targeted by 
small molecules (Fairlie et al., 2008). As a possible drug or drug design, peptide 
P1 identified from a 7-mere random peptide library was screened against P. 
falciparum infected red blood cells (iRBCs) to identify distinctions on the surface 
from uninfected erythrocytes. Peptide P1 when conjugated with a peptide having 
moderate hemolytic activity showed inhibition of parasite growth (Eda, Eda, & 
Sherman, 2004). A 20-aa peptide (R1) identified from a random peptide library 
binds to AMA1 and inhibits invasion. During erythrocyte invasion AMA1 binds to 
RON2 complex to form the moving junction. Crystal structures of AMA-RON2 
and AMA-R1 reveal structural mimicry and will help identify key residues (Harris 
et al., 2005; Vulliez-Le Normand et al., 2012). 
As a possible diagnostic antibody fragment; two novel binders to P. 
falciparum histidine rich protein 2 (rPfHRP2), identified by screening a human 
naïve scFv antibody library, have comparable specificities to PfHRP2-specific 
mouse mAb C1-13 and is more stable, making it a possible tool for point of care 
diagnostics (Leow, Jones, Cheng, Mahler, & McCarthy, 2014). Fab-phage 
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display library was made from peripheral blood leukocytes’ mRNA from clinically 
immune individuals and biopanned against merozoite surface antigen 3 (MSP-3) 
residues 194 to 257. Of the 3 Fab fragments identified one, RAM1, showed 
antiparasitic effect (Lundquist et al., 2006). 
Subunit vaccine studies have identified a 69-aa peptide F2i that binds to 
Glycophorin B on RBC and inhibits binding of erythrocyte-binding ligand-1 (EBL-
1) on the merozoite. F2i was identified through screening using P. falciparum 
cDNA phage display library and purified glycophorin and RBCs (Li et al., 2012). 
Transmission blocking vaccine studies on Female Gamete peptide 1 (FGP1) that 
binds specifically to the surface of female P. berghei gametes and strongly 
reduces P. berghei oocyst formation by interfering with fertilization could be 
considered as a transmission blocking vaccine supplementary target (Vega-
Rodriguez, Perez-Barreto, Ruiz-Reyes, & Jacobs-Lorena, 2015). Single-chain Fv 
fragments (scFv)-phage display libraries derived from malaria immune patients 
was panned against Pfs48/45, a gamete surface protein of the sexual stages of 
P. falciparum. Identified human scFv antibodies specific for epitope III of 
Pfs48/45 could be used to arrest the sporogenic stages inside the mosquito 
(Roeffen et al., 2001).  
Epitope mapping of conformation dependent mAb4G2dc1 that binds to P. 
falciparum AMA1, critical for erythrocyte invasion (Kocken et al., 1998) was 
carried out using phage displayed peptide library identifying three peptides that 
bind to 4G2dc1 and mimic an important epitope of AMA1 (Casey et al., 2004; 
Sabo et al., 2007). Phage display and crystal structure was also used to map the 
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epitope of mAb 45B1 to a conserved region of PyAMA1 which is a region that is 
also recognized by inhibitory mAb 4G2 that is specific for PfAMA1 (David L. 
Narum, Ogun, Batchelor, & Holder, 2006). Passive immunization with mAb 45B1 
specific for P. yoelii AMA1 was protective against a lethal challenge infection with 
P. yoelii (D. L. Narum, Ogun, Thomas, & Holder, 2000). 
Specifically for DBP, three binding inhibitory single-chain variable 
fragment (scFv) antibodies were identified from a library constructed from 3 
human patients infected with P. vivax panned on DBPII (Kim et al., 2007). 
Antibody surrogates as randomized fragments on diverse scaffold proteins 
and designing catalytic antibodies (abzymes) or enzymes with novel specificities 
are fields that phage display has not yet been used to analyze and overcome the 
various challenges posed by the malarial parasite.  
 
Phage display library 
In 1997, Fack and co-workers compared the efficiencies of epitope 
mapping using phage display by random peptide phage display libraries and by 
gene-fragment libraries in combination with peptide scan. A single round of 
panning using the gene-fragment library was enough to affinity select for the 
peptides corresponding to the respective epitopes of the mAbs. Random peptide 
library however was successful for only two of the mAbs after three to four 
rounds of panning (Fack et al., 1997).  
In 2001, Coley et al. studied epitope mapping in the malaria antigen, 
AMA1. They used a combination of techniques, first the antigen fragments 
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identifies the location of the epitopes then random peptide libraries used to 
accurately identify amino acids involved in the epitope and finally, phage display 
of mutant fragments confirms the role of each residue in the epitope. A panel of 
mAbs was generated to obtain binding reagents to the various domains within 
the molecule. It was determined that MAb 5G8 recognizes a short linear epitope 
within the pro-domain of AMA1 while the epitope recognized by MAb 1F9 is 
reduction sensitive and resides in domain-1, within a disulphide-bonded 57 
amino acid sub-domain (Coley et al., 2001). This study is worth emulating for P. 
vivax DBP.  
Epitope mapping using phage display has been mainly focused on the use 
of random peptide libraries and gene fragments libraries derived from selected P. 
falciparum proteins. This study, aims to use P. vivax DBPII gene fragment 
libraries to determine the epitopes of various inhibitory and non-inhibitory mAbs 
by biopanning. In addition, a mAb with linear epitope was panned against a 
random 20-aa peptide library while antibodies with conformational dependent 
epitopes were biopanned against a random helical scaffold, Affibody library. 
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Figure 1.1: Countries with ongoing transmission of malaria in 2013. Reprinted 
from Publication World Malaria Report 2014, World Health Organization, 
Introduction, Pages No. 2, Copyright (2014) 
 
 
 
 
 
 
 
 
 
Figure 1.2: Spatial distribution of P.vivax malaria endemicity in 2010 
(Gething et al., 2012) 
 
2 | WORLD MALARIA REPORT 2014
The World malaria report 2014 summarizes the status of global e!orts 
to control and eliminate malaria. The report is produced every year by the 
WHO Global Malaria Programme, with the help of WHO regional and country 
offices, ministries of health in endemic countries, and a broad range of other 
partners. Data for this year’s report were assembled from 97 countries and 
territories with ongoing malaria transmission, and an additional six countries 
that are working to prevent reintroduction. 
This section outlines the public health burden posed by malaria, the 
strategies that can be used to reduce that burden, and the goals, targets 
and indicators that have been set for 2015. The report then reviews global 
progress towards the goals and targets in relation to funding (Section 2), 
intervention coverage (Sections 3–7), and malaria cases and deaths 
(Section 8). The review is followed by Regional pro!les that summarize 
trends in each WHO region. Country pro!les are provided both for countries 
with ongoing malaria transmission and for those recently achieving zero local 
cases. Finally, annexes provide sources of data, details of the methodology 
used in the analysis, and tables containing country and regional data.
1.1 The public health challenge posed by 
malaria
Malaria transmission occurs in all six WHO regions. Globally, an 
estimated 3.3 billion people in 97 countries and territories are at risk of being 
infected with malaria and developing disease (Figure 1.1), and 1.2 billion are 
at high risk (>1 in 1000 chance of getting malaria in a year). According to 
the latest estimates, 198 million cases of malaria occurred globally in 2013 
(uncertainty range 124–283 million) and the disease led to 584 000 deaths 
(uncertainty range 367 000–755 000), representing a decrease in malaria 
case incidence and mortality rates of 30% and 47% since 2000, respectively. 
The burden is heaviest in the WHO African Region, where an estimated 90% 
of all malaria deaths occur, and in children aged under 5 years, who account 
for 78% of all deaths.
DATA WERE ASSEMBLED FROM 
97 COUNTRIES AND TERRITORIES 
WITH ONGOING MALARIA 
TRANSMISSION, AND AN 
ADDITIONAL SIX COUNTRIES 
WORKING TO PREVENT 
REINTRODUCTION.
1. INTRODUCTION
Figure 1.1 Countries with ongoing transmission of malaria, 2013
Source: National malaria control programme reports
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Figure 1.3: Malaria life cycle (Arama & Troye-Blomberg, 2014) Journal of internal 
medicine by BLACKWELL PUBLISHING LTD.. Reproduced with permission of 
BLACKWELL PUBLISHING LTD 
 
 
 
 
 
 
midgut to form a zygote and subsequently a motile
ookinete. Okinetes penetrate the midgut epithelial
cells and rest between the midgut epithelium and
the basal lamina to form oocysts. The oocysts
undergo a complex asexual development stage,
which eventually generates infective sporozoites
that can be introduced into the human host at the
next blood meal via the mosquito saliva, thereby
ensuring the continuation of the parasite life cycle.
Vaccines against malaria
The purpose of vaccination strategies is to induce
protective memory immune responses in advance
of infection, to provide protection in the case of
encountering the disease-causing agent again.
Malaria vaccine development is an active research
area with enormous challenges. As the parasite
proceeds from a sporozoite through the liver stage
to the replicating cycle of the blood stage, it
undergoes morphological changes and displays
antigenic variations. This allows the parasite to
evade the protective immune responses of the host.
As a result, the acquisition of long-term sterile
immunity, which is often associated with recovery
from many other infectious diseases, is not
observed in malaria-infected individuals. Despite
these difficulties, the most convincing evidence
Mosquito inoculating 
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Fig. 1 The life cycle of Plasmodium falciparum. The life cycle of P. falciparum in humans consists of the pre-erythrocytic
stage, the asexual blood stage and the gametocyte stage. This life cycle involves humans and female Anopheles mo quitoes.
Each stage can be characterized by the expression of stage-specific proteins that are targets of host immune responses. The
potential immune mechanisms induced at each stage are shown. RBC, red blood cell; NK, natural killer; ROS, reactive
oxygen species.
C. Arama & M. Troye-Blomberg Review: Recent advances in malaria vaccine development
458 ª 2014 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2014, 275; 456–466
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Figure 1.4: Merozoite Invasion of Erythrocytes (Zimmerman, Ferreira, Howes, & 
Mercereau-Puijalon, 2013) ADVANCES IN PARASITOLOGY by ACADEMIC 
PRESS. Reproduced with permission of ACADEMIC PRESS 
 
 
 
 
 
 
 
Red Blood Cell Polymorphism and Susceptibility to Plasmodium vivax 63
Figure 2.8 Overview of P. vivax merozoite interaction with the human red blood 
cell. Initial attachment occurs between any part of the merozoite (blue) and eryth-
rocyte (red). The merozoite reorients, positioning its apical end for attachment to 
the red cell membrane. A junction forms between the apical end of the merozo-
ite and the erythrocyte membrane of Duffy-positive cells (first call-out box). In 
contrast, P. knowlesi electron microscopy has shown thin filaments between the 
merozoite apical end and the Duffy-negative red cell membrane; however, the 
merozoite is not drawn into contact with the red cell and the junction fails to form. 
This has implied that junction formation fails to occur between P. vivax and the 
Duffy-negative red cell membrane as well (second call-out box). Once a durable 
junction has formed between the merozoite and the red cell, micronemes (green) 
and rhopteries (dark blue) release their contents, the red cell membrane invagi-
nates and the merozoite moves into the parasitophorous vacuole (third call-out 
box). Movement of the gliding junction is complete once the merozoite is engulfed 
within the parasitophorous vacuole and the orifice at the red cell membrane is 
sealed (fourth call-out box). (For interpretation of the references to colour in this 
figure legend, the reader is referred to the online version of this book.)
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Figure 1.5: Schematic drawing of the important structural domains of DBP. 
Where TM, transmembrane domain and Cyto, cytoplasmic domain (VanBuskirk, 
Sevova, et al., 2004) Copyright (2004) National Academy of Sciences, U.S.A.	  
 
 
 
 
 
 
 
Figure 1.6: Crystal structure of PvDBPII. Monomers of DBPII are colored green 
and yellow (A) overlay of polymorphic residues (blue) and critical receptor-
binding residues (purple) (B) epitopes recognized by blocking antibodies (red, 
most significant; brown, significant), which include the dimer interface and 
DARC-binding groove. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Structural & Molecular Biology (Batchelor et al., 2011), copyright (2011)  
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Consistent with our SAXS and AUC measurements, ITC indicated 
that the complex has a stoichiometry of 1:1 RII-PvDBP and DARC1–60 
(Supplementary Methods, Supplementary Fig. 6b). Together, these 
results demonstrate that the receptor-bound complex contains two 
molecules of RII-PvDBP bound to two molecules of DARC1–60.
It is clear that the concentrations of full receptor and ligand required to 
induce dimerization and binding in vivo will be much lower than the range 
studied here, given that our experiments were performed on the isolated 
soluble RII-PvDBP domain and a small fragment of DARC (60 residues). 
Membrane anchoring of both PvDBP and DARC in vivo, in addition to the 
dimeric nature of DARC16, will increase the propensity to dimerize even 
further. Lastly, the addition of a sulfate group on DARC1–60 is expected 
to further increase affinity for PvDBP and drive dimerization.
Functional regions of RII-PvDBP are under selective pressure
To visualize the effects of selective pressure on RII-PvDBP and test our 
receptor induced dimerization model, we mapped onto the structure 
known PvDBP polymorphisms and amino acid substitutions that 
affect RBC rosetting (Fig. 3a–c and Supplementary Fig. 7)20,23,25,26. 
As the DARC-binding groove and RII-PvDBP dimer interface are 
functionally critical, receptor-induced dimerization predicts that 
functional regions will be underrepresented by polymorphic residues 
and overrepresented by residues essential for DARC recognition.
As expected, regions spanning the DARC-binding groove and dimer 
interface are devoid of documented polymorphic residues and heavily 
represented in essential residues (Fig. 3a–c and Supplementary Fig. 7). 
Polymorphisms are spread across nonfunctional regions, suggesting 
that the parasite generates variations in nonfunctional residues spread 
throughout the DBL domain for immune evasion.
Blocking-antibodies target functional regions of RII-PvDBP
The humoral immune response has an important role during the 
pathogenesis of malaria. Receptor-induced dimerization predicts 
epitopes recognized by blocking antibodies against PvDBP will map 
to the DARC-binding groove or dimer interface. We mapped onto 
the structure epitopes targeted by blocking antibodies from sera of 
individuals with naturally acquired immunity to P. vivax (Fig. 3d and 
Supplementary Fig. 7)22. Five epitopes that correlated significantly 
(P < 0.05 (ref. 22)) with a block in PvDBP RBC rosetting are located 
in subdomain 2 of RII-PvDBP.
Mapping these five epitopes reveals that the DARC-binding groove 
and dimer interface are composed of the most significant epitope and 
surrounded by the four remaining epitopes (Fig. 3d and Supplementary 
Fig. 7). These results suggest that protective antibodies target functional 
regions in RII-PvDBP, leading to disruption of dimerization and/or 
prevention of receptor binding. Mapping blocking antibody epitopes 
onto PvDBP shows the importance of the DARC-binding groove and 
PvDBP dimerization in vivo and identifies structural regions targeted 
by the adaptive immune system in response to P. vivax.
The minimal binding domain and asymmetric flap of RII-PvDBP
The minimal region of RII-PvDBP required to bind RBCs extends from 
residues 256 to 426, spanning cysteines 4–8 (ref. 27). This includes 
a
c d
bRII-PvDBP, 1 mg ml–1
RII-PvDBP–DARC1–60, 1 mg ml
–1 
RII-PvDBP, 6 mg ml–1
100 1,000
100
10
1
0.1
1,000
100
10
1
0.1
90 400
40
0 0.1
9
0 0.1
0.1
0.1
0
10
100
68
0
680
10
I(
Q
)
I(
Q
)
I(
Q
)
I(
Q
)
100
10
1
0.1
0 0.1
RII-PvDBP DARC1–60
0.2 0.3
1
0.1
0 0.1 0.2
Dimer ?2 = 2.17
Monomer ?2 = 3.11
RII-PvDBP DARC1–60
Dimer ?2 = 1.53
Monomer ?2 = 9.50 
Q (Å–1)
Q (Å–1) Q (Å–1)
Q (Å–1)
0 0.1 0.2 0.3
0.3 0 0.1 0.2 0.3
RII-PvDBP
Dimer ?2 = 4.02
Monomer ?2 = 4.01
RII-PvDBP
Dimer ?2 = 3.08
Monomer ?2 = 1.20
RII-PvDBP–DARC1–60, 6 mg ml
–1
Figure 2 DARC binding drives dimerization of RII-PvDBP. Experimental 
(black) and theoretical SAXS plots of scattering intensity (I) against 
scattering momentum (Q) for the monomer (blue) and dimer (red) at 
different concentrations. An expanded plot of the low-angle data (0 < Q < 
0.1) that clearly delineates oligomeric state is shown in the top right insert.  
Ab initio reconstructions are overlaid on structures (bottom left insert) with 
monomers colored in green and yellow and molecular envelopes in sand. 
(a) RII-PvDBP at 1 mg ml−1. (b) RII-PvDBP at 6 mg ml−1. (c) RII-PvDBP–
DARC1–60 at 1 mg ml−1. (d) RII-PvDBP–DARC1–60 at 6 mg ml−1.
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Figure 3 The sulfotyrosine pocket, DARC-binding groove and dimer 
interface are under selective pressure and are targeted by blocking 
antibodies. Monomers are in green and yellow. (a) Polymorphic 
residues20,23 (blue) are excluded from the dimer interface but are 
evenly distributed over the remaining RII-PvDBP surface. (b) Amino 
acid substitutions that abrogate RBC rosetting25,26 (purple) map to the 
DARC-binding groove and dimer interface. (c) Overlay of polymorphic 
residues (blue) and critical receptor-binding residues (purple) on the 
dimer. The DARC-binding groove at the dimer interface is composed of 
essential residues and devoid of polymorphisms. (d) Epitopes recognized 
by blocking antibodies22 (red, most significant; brown, significant) map 
to the functional regions of RII-PvDBP, which include the dimer interface 
and DARC-binding groove. (e) The minimal binding domain of RII-PvDBP 
(residues 256–426)27 contains the full dimer interface and DARC-binding 
groove. (f) A global view of the dimer, which shows that the asymmetric 
flap is disordered in chain A. Essential residues are colored in purple. (g) A 
detailed view of the asymmetric flap shows that this region contains several 
essential residues, suggesting a second potential DARC-binding site. 
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Consistent with our SAXS and AUC measurements, ITC indicated 
that the complex has a stoichiometry of 1:1 RII-PvDBP and DARC1–60 
(Supplementary Methods, Supplementary Fig. 6b). Together, these 
results demonstrate that the receptor-bound complex contains two 
molecules of RII-PvDBP bound to two molecules of DARC1–60.
It is clear that the concentrations of full receptor and ligand required to 
induce dimerization and binding in vivo will be much lower than the range 
studied here, given that our experiments were performed on the isolated 
soluble RII-PvDBP domain and a small fragment of DARC (60 residues). 
Membrane anchoring of both PvDBP and DARC in vivo, in addition to the 
dimeric nature of DARC16, will increase the propensity to dimerize even 
further. Lastly, the addition of a sulfate group on DARC1–60 is expected 
to further increase affinity for PvDBP and drive dimerization.
Functional regions of RII-PvDBP ar  under selective pressure
To visualize the effects of selective pressure on RII-PvDBP and test our 
receptor in uc  dimerization model, we mapped onto the structure 
known PvDBP polymorphisms and amino acid substitutions that 
affect RBC rosetting (F g. 3a–c and Supplementary Fig. 7)20,23,25,26. 
As the DARC-binding groove and RII-PvDBP dimer interface are 
functionally critical, receptor-induced dimerization predicts that 
function l regions will be underrepresented by polymorphic residues 
and overrepresented by residues essential for DARC recognition.
As expected, regions spanning the DARC-binding groove and dimer 
interface are devoid of documented polymorphic residues and heavily 
represented in essential residues (Fig. 3a–c and Supplementary Fig. 7). 
Polymorphisms are spread across nonfunctional regions, suggesting 
that the parasite generates variations in nonfunctional residues spread 
throughout the DBL domain for immune evasion.
Blocking-antibodies target functional regions of RII-PvDBP
The humoral immune response has an important role during the 
pathogenesis of malaria. Receptor-induced dimerization predicts 
epitopes recognized by blocking antibodies against PvDBP will map 
to the DARC-binding groove or dimer interface. We mapped onto 
the structure epitopes targeted by blocking antibodies from sera of 
individuals with naturally acquired immunity to P. vivax (Fig. 3d and 
Supplementary Fig. 7)22. Five ep topes that correlated significantly 
(P < 0.05 ( ef. 22)) with a block in PvDBP RBC rosetting are located 
in subdomain 2 of RII-PvDBP.
Mapping these five epitopes reveals that the DARC-binding groove 
and dimer interface are composed of the most significant epitope and 
surrounded by the four remaining epitopes (Fig. 3d and Supplementary 
Fig. 7). These results suggest that protective antibodies target functional 
regions in RII-PvDBP, leading to disruption of dimerization and/or 
prevention of receptor binding. Mapping blocking antibody epitopes 
onto PvDBP shows the importance of the DARC-binding groove and 
PvDBP dimerization in vivo and identifies structural regions targeted 
by the adaptive immune system in response to P. vivax.
The minimal binding domain and asymmetric flap of RII-PvDBP
The minimal region of RII-PvDBP required to bind RBCs extends from 
residues 256 to 426, spanning cysteines 4–8 (ref. 27). This includes 
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interface are under selective pr ssure and are targeted by blocking 
antibodies. Monomers are in green and yellow. (a) Polymorphic 
residues20,23 (blue) are excluded from the dimer interface but are 
evenly distributed over the remaining RII-PvDBP surface. (b) Amino 
acid substitutions that abrogate RBC rosetting25,26 (purple) map to the 
DARC-binding groove and dimer interface. (c) Overlay of polymorphic 
residues (blue) and critical receptor-binding residues (purple) on the 
dimer. The DARC-binding groove at the dimer interface is composed of 
essential residues and devoid of polymorphisms. (d) Epitopes recognized 
by blocking antibodies22 (red, most significant; brown, significant) map 
to the functional regions of RII-PvDBP, which include the dimer interface 
and DARC-binding groove. (e) The minimal binding domain of RII-PvDBP 
(residues 256–426)27 contains the full dimer interface and DARC-binding 
groove. (f) A global view of the dimer, which shows that the asymmetric 
flap is disordered in chain A. Essential residues are colored in purple. (g) A 
detailed view of the asymmetric flap shows that this region contains several 
essential residues, suggesting a second potential DARC-binding site. 
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Figure 1.7: ‘DEK’ epitope and putative sulfotyrosine-binding pocket on PvDBPII 
crystal structure (Batchelor et al., 2014; Batchelor et al., 2011). DBPII monomers 
are colored green and yellow (A) DBPII:DARC heterotetramer with DACR 
ectodomain helical monomers in pink and purple. Polymorphic residues in blue 
and the most polymorphic region called the ‘DEK’ epitope, (B) Putative 
sulfotyrosine-binding pocket in red. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Structural & Molecular Biology (Batchelor et al., 2011), 
copyright (2011) 
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within DBP-RII and the structural orientation of each molecule
provide insight into the mechanisms of antibody inhibition of P.
vivax RBC invasion. It appears that antibodies targeting DBP-RII
are capable of preventing DARC binding by recognizing DBP-
RII’s RBC proximal surface, DARC recognition sites, or the
homodimeric interface, and may block invasion using other,
currently unidentified mechanisms.
The crystallographic and ITC solution studies presented here
support a step-wise binding model in which receptor-induced
DBP-RII dimerization facilitates formation of a heterotrimer that
subsequently recruits a second DARC molecule to form a
heterotetramer (Fig. 8). Due to avidity contributions to binding
inherent in a two-site mechanism, this heterotetrameric complex
may enable the observed tight binding of P. vivax to the RBC
membrane. Since recombinant DBP-RII is monomeric in the
absence of DARC when examined in solution [26], the dimer
interface and DARC binding pockets are exposed and accessible
to antibodies prior to DARC engagement. DARC is known to
exist as a homodimeric and heterodimeric GPCR [36]. The
heterotrimer and heterotetramer could represent DBP-RII bind-
ing to a DARC heterodimer or homodimer, respectively. The
observed transitions may be a selectivity mechanism for DBP-RII
to preferentially bind homodimeric DARC while maintaining the
ability to bind to a DARC heterodimer. The binding model
proposed here is applicable to other DBL domain proteins that
may oligomerize upon receptor binding [9,26,37–39]. Since
dimerization is prevalent in receptor signaling, it is plausible that
complex assembly initiates a signal through the transmembrane
and cytoplasmic domains of DBP to activate pathways of invasion.
Although structure determination of the DBP-RII:DARC
complexes allows for visualization and identification of critical
contact points, the relevance of each intermediate to complex
assembly in solution is not immediately known from the static
pictures of binding. To begin to assess the biological role of
complex assembly, we utilized ITC to demonstrate that two
binding events corresponding to the formation of a heterotrimer
and heterotetramer exist in solution. We further tested mutant
DBP-RII constructs for RBC binding and demonstrated that these
mutations ablate binding t RBCs, supporting the biological role
of the DARC contacts identified here as well as the role of the
dimer interface. In addition, the large buried surface area for both
DARC binding sites and the ITC measurements suggest high
affinity interactions. This study thus unambiguously identifies
DARC residues 19–30 as a critical binding element that interacts
with DBP residues L270-K289, Q356-K367 and F261-T266.
The biphasic profile obtained by ITC is different from studies
previously reported where a single binding event with a molar
ratio of 1 was observed indicative of the heterotetramer [26]. This
difference is likely due to the buffer conditions used in each case.
In prior studies, titrations were performed at a salt concentration
of 50 mM while the studies presented here were performed in PBS
to examine binding under physiological conditions. These results
suggest that observation of the heterotrimer intermediary step by
ITC is salt dependent. Never-the-less, the biphasic profile and step
wise binding mechanism presented here are representative of the
assembly mechanism under physiologically relevant conditions.
Figure 7. Mapping polymorphic residues and inhibitory
epitopes reveals targets of selective pressure. DBP-RII molecules
are in green and yellow. DARC molecules are in purple and blue. DARC
residue labels are underlined. (A) Nonsynonymous DARC polymor-
phisms in primates, residues colored in blue, which make critical
contacts with DBP-RII provide a mechanism for inter-species transmis-
sion barriers. (B) Polymorphic DBP residues, in blue, are spread
throughout the molecule. The most polymorphic region of DBP is the
‘‘DEK epitope’’ opposite the DARC14–43 binding site. (C) Inhibitory
epitopes, in red and brown, map to the heterotetramer interface, DARC
binding pockets and RBC proximal face of DBP-RII.
doi:10.1371/journal.ppat.1003869.g007
DBP Engagement of DARC
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170 residues of the 314-residue RII-PvDBP construct. Notably, this 
minimal binding domain retains all dimerization determinants and 
the putative sulfotyrosine-binding pocket, further indicating that 
the functional elements defined in this study are critical for DARC 
recognition (Fig. 3e and Supplementary Fig. 7).
In the RII-PvDBP structure, residues 291–299 and 365–377 surround 
the DARC-binding groove (Fig. 3f,g). In chain A, but not chain B, res-
idues 365–377 are disordered, indicative of flexibility (Fig. 3f,g). We 
therefore termed the region spanning residues 291–299 and 365–377 
the asymmetric flap. These residues are not part of the putative 
sulfotyrosine-binding pocket but are required for DARC binding. 
Thus, we propose that these residues form a second DARC contact. 
DARC
1–60
 binding may stabilize the asymmetric flap to form a 
tight complex.
VAR2CSA shares the dimer interface and receptor-binding site
To test the generality of our receptor-mediated ligand-dimerization 
model, we examined receptor recognition by other DBL domains. 
The VAR2CSA variant of PfEMP1 is the primary virulence deter-
minant for placental malaria and is associated with an estimated 
75,000–200,000 infant deaths each year
28
. VAR2CSA is expressed on 
the surface of infected erythrocytes and binds specifically to chon-
droitin sulfate proteoglycans (CSPG) in the intervillous space of the 
placenta
29
. VAR2CSA contains six DBL domains, which can indi-
vidually bind CSPG
30
. A recent study has reported the structure of 
VAR2CSA domain DBL6?
31
; the sixth DBL domain of VAR2CSA. 
DBL6? crystallized with two copies in the asymmetric unit but was 
proposed to function as monomer, analogously to PkDBP.
We examined the crystal symmetry for the DBL6? structure and 
found an unreported crystal-packing contact that is identical to 
RII-PvDBP’s dimer interface (Fig. 4a). Mutagenesis of several basic 
patches in DBL6? identified two lysines, at positions 2392 and 2395, 
as essential for CSPG binding
31
. Notably, these lysines align to RII-
PvDBP’s putative sulfotyrosine-binding pocket (Fig. 4b), with DBL6? 
Lys2392 occupying the location of RII-PvDBP Arg274 and DBL6? 
Lys2395 occupying the location of RII-PvDBP Lys273 (Fig. 4b). 
Lys2395 is also close to an acidic residue on the opposing subunit 
at the dimer interface, in a configuration analogous to the Arg274-
Glu249 salt bridge. Thus, DBL6? may dimerize and bind its receptor 
in a manner similar to RII-PvDBP. Further examination of the oligo-
meric state of DBL6? is warranted and could explain the greater recep-
tor specificity and affinity of full-length VAR2CSA as compared to 
individual domains
30
.
DISCUSSION
In an effort to elucidate the molecular basis and mechanism of recep-
tor recognition by PvDBP, we performed a structural, functional and 
mechanistic study of RII-PvDBP’s interaction with the N terminus of 
DARC. We showed that RII-PvDBP’s receptor-binding site is formed 
by a RII-PvDBP homodimer and that disruption and restoration of 
dimerization disrupts and restores RBC binding. We also demon-
strated that dimerization is critical for, and driven by, receptor binding 
that leads to the formation of a complex composed of two PvDBP 
and two DARC. Finally, we showed that recognition of DARC occurs 
concomitantly with dimerization of PvDBP, placing the N termini 
of DARC in the DARC-binding groove created upon dimerization. 
Thus, receptor recognition by PvDBP is through receptor-mediated 
ligand dimerization (Fig. 5). This model is applicable to receptor 
recognition by DBL domains from PvDBP, PfEMP1 VAR2CSA and 
PfEBA-175 (ref. 32).
This model is consistent with structural and functional studies of 
PfEBA-175 that have proposed a dimeric RII-PfEBA-175 assembly 
upon receptor binding
32
. A subsequent crystal structure of RII-PkDBP 
from P. knowlesi DBP suggested that this domain binds to DARC as a 
monomer because no dimeric contacts were observed in the crystal 
structure
24
, which is inconsistent with the data presented here. It is 
likely that the RII-PkDBP structure is not dimeric, as these crystals 
were grown in detergent (0.5% N-octyl-?-d-glucopyranoside), which 
would disrupt biologically relevant oligomerization. Although the 
differences in the models may be due to interspecies differences, the 
structure of monomeric RII-PkDBP could represent the unbound 
monomer that dimerizes upon receptor binding.
Singh et al. further proposed a sulfotyrosine-binding pocket
24
, 
although no direct interaction studies were presented. Furthermore, 
the monomeric model of binding and the putative binding pocket 
cannot account for all mutations that affect binding to DARC reported 
in the literature
25,26
. The authors also proposed a ‘just-in-time release’ 
strategy of immune evasion based on mapping of a subset of polymor-
phic residues to a face on the opposite side of their proposed DARC-
binding site
24
. However, polymorphisms are more widely dispersed 
than those examined by Singh et al.
33
 and cannot be accounted for by 
the monomeric model or just-in-time release strategy.
The receptor-mediated ligand dimerization model proposed here 
clarifies the mutational, polymorphism and antibody data for PvDBP. 
This model indicates that mutations can be grouped into residues that 
affect the dimer interface, the putative sulfotyrosine-binding pocket, 
the DARC-binding groove and the asymmetric flap. Our data strongly 
VAR2CSA DBL6?
Reported structure
VAR2CSA DBL6?
Reorganized by crystal symmetry
CSPG binding site
RII-PvDBP
DARC-binding groove
Lys2392
Gln356
Arg274
Lys273Lys2395
a b
Figure 4 RII-PvDBP’s dimer interface and receptor binding site are conserved in VAR2CSA DBL6?. (a) Examination of th  crystal packing interfaces 
for VAR2CSA DBL6? revealed a dimeric organization identical to the RII-PvDBP dimer. Critical VAR2CSA DBL6? binding residues are shown in red 
and map to the putative sulfotyrosine-binding pocket, indicating that both the receptor-binding pocket and dimer interface are conserved in these two 
DBL domains. Monomers are colored green and yellow in both cases. Top, reported asymmetric unit for DBL6?; middle, reorganized dimer based solely 
on crystal symmetry; bottom. RII-PvDBP dimer. (b) Overlay of RII-PvDBP (green) and DBL6? (brown) reveals critical binding residues for each protein 
superpose well (Lys273 and Arg274 from RII-PvDBP, and Lys2392 and Lys2395 from DBL6?).
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CHAPTER TWO: 
DEFINING THE IMMUNOREACTIVE SURFACE OF PLASMODIUM VIVAX 
DUFFY BINDING PROTEIN REGION II 
 
ABSTRACT 
Plasmodium vivax Duffy binding protein region II (DBPII) is an essential 
ligand for reticulocyte invasion, thereby making this molecule an attractive 
vaccine candidate against asexual blood-stage P. vivax. However, strain-specific 
immunity due to DBPII allelic variation may complicate vaccine efficacy, 
suggesting that an effective DBPII vaccine needs to target immune response to 
conserved epitopes that are potential targets of strain-transcending neutralizing 
immunity. Anti DBPII mAbs, which were previously functionally characterized by 
in vitro COS7 cell binding assay as inhibitory and non-inhibitory to DBPII-
erythrocyte binding, were mapped to DBPII gene fragment libraries using phage 
display. Inhibitory mAb 3C9 binds to a conserved conformation-dependent 
epitope in subdomain 3 while non-inhibitory mAb 3D10 binds to a linear epitope 
in subdomain 1 of DBPII. In addition, more definitive epitope mapping of mAb 
3D10 was achieved using a random peptide library displayed on phage. To 
determine the potential of these minimal peptide epitopes to function as an 
epitope-specific vaccine, their immunogenicity to induce functionally inhibitory 
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antibodies were evaluated. The mAb 3C9 epitope elicited antibodies that 
inhibited DBP binding to erythrocytes whereas mAb 3D10 epitope did not.            
 
INTRODUCTION 
Plasmodium vivax is the second most prevalent cause of human malaria 
and is globally the most widely distributed leaving about 40% of the world’s 
population at risk (Gething et al., 2012). Although vivax malaria is historically 
called ‘benign tertian malaria’ (Garnham, 1951) there have been increasing 
reports of clinical severity with emerging virulent forms of the parasite (Alexandre 
et al., 2010; Kochar et al., 2009), recurrent clinical episodes due to reactivation of 
the dormant forms in the liver (Krotoski et al., 1982) and widespread drug 
resistance (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann, Davis, & 
Hutton, 1989) (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann et al., 
1989), which potentially includes strains with low sensitivity to primaquine, the 
only drug against relapse, or in people with a poor ability to metabolize the drug 
to its active form (Baird & Hoffman, 2004; Bennett et al., 2013; Pybus et al., 
2013). There is an urgent need to develop new therapies, especially a vaccine to 
control and prevent vivax malaria. Immunity to asexual blood stage antigens is 
especially to those that play a role in merozoite invasion of erythrocyte. 
Merozoite antigens are believed to be an important component of naturally 
acquired immunity to malaria (Marsh & Kinyanjui, 2006; Yazdani, Mukherjee, 
Chauhan, & Chitnis, 2006), and represents ideal candidates for vaccine 
mediated-immunity against blood stage infection (Mueller et al., 2013). 
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Plasmodium vivax Duffy binding protein (PvDBP) binds to its cognate receptor 
Duffy antigen receptor for chemokines (DARC) on reticulocytes forming an 
irreversible junction, critical for merozoite invasion (Adams et al., 1990; Adams et 
al., 1992; Chitnis, Chaudhuri, Horuk, Pogo, & Miller, 1996; Miller et al., 1976; 
Miller, Mason, Dvorak, McGinniss, & Rothman, 1975; Wertheimer & Barnwell, 
1989). In most circumstances P. vivax merozoites almost exclusively use DARC 
as a receptor to invade reticulocytes (Miller et al., 1976). However, more recently, 
there have been a few P. vivax cases reported among Duffy negative individuals 
(Cavasini et al., 2007; Menard et al., 2013; Ryan et al., 2006), although an 
alternate receptor-ligand invasion pathway is unknown. Hence PvDBP remains a 
prime candidate for vaccine-induced immunity against blood stage P. vivax 
infection. 
Plasmodium vivax DBP is a type I membrane protein localized to the 
merozoite micronemes and is a member of the Duffy binding-like erythrocyte-
binding proteins (DBL-EBP) family characterized by two conserved cysteine rich 
domains (Adams et al., 1990; Adams et al., 1992) The DBL-EBP and share 
similar molecular structures and functional characteristics (Adams et al., 2001; 
Adams et al., 1990; Adams et al., 1992; Mayer, Kaneko, Hudson-Taylor, Reid, & 
Miller, 2001; D. L. Narum, Fuhrmann, Luu, & Sim, 2002). A 330 amino acid 
region within the extracellular portion of DBP, also known as DBP region II 
(DBPII) constitutes the principal determinants for receptor recognition (Adams et 
al., 1992; Chitnis & Miller, 1994; Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et 
al., 2004). The central region of DBPII is highly polymorphic (Ampudia et al., 
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1996; Tsuboi et al., 1994; Xainli et al., 2000), in a pattern consistent with high 
immune selection pressure on DBPII (Baum, Thomas, & Conway, 2003; Baum, 
Ward, & Conway, 2002). Residues critical for receptor recognition are flanked by 
polymorphic residues that are not important for binding to the receptor (Batchelor 
et al., 2011; VanBuskirk, Sevova, et al., 2004; Xainli et al., 2000). These 
polymorphisms represent a potential challenge to developing a vaccine since 
they contribute to strain-specificity in naturally-acquired immunity (J. L. Cole-
Tobian et al., 2009; McHenry, Barnes, Ntumngia, King, & Adams, 2011; 
Ntumngia et al., 2012b; VanBuskirk, Cole-Tobian, et al., 2004). 
In endemic regions, individuals develop anti-DBPII antibodies, which 
increase with age, suggesting a boosting effect from repeated exposure to 
infection (King et al., 2008; P. Michon, Fraser, & Adams, 2000). Furthermore, 
anti-DBP antibodies tend to be weak, short-lived and strain-specific (Ceravolo et 
al., 2009; King et al., 2008; Xainli et al., 2003) with allelic differences appearing 
to be driven by immune selection (McHenry et al., 2011; VanBuskirk, Cole-
Tobian, et al., 2004). Few individuals develop high titers of broadly reactive, 
invasion-inhibitory anti-DBPII antibodies (Chootong et al., 2010; J. L. Cole-
Tobian et al., 2009; King et al., 2008). These data are all consistent with the 
hypothesis that variation is an immune evasion mechanism responsible for 
strain-specific immunity and that stable, broadly inhibitory immunity is achieved 
when antibodies target functionally conserved epitopes. 
Phage display has been a useful tool for epitope mapping with the 
advantages of rapidly producing refolded protein, fused to phage coat; forming a 
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traceable link back to the genotype (Smith, 1985; Wilson & Finlay, 1998). In 
malaria, phage display has been used to map epitopes on apical membrane 
antigen 1 (AMA1) (Casey et al., 2004; Coley et al., 2001; David L. Narum et al., 
2006; Sabo et al., 2007), merozoite surface protein (MSP) (Demangel, Lafaye, & 
Mazie, 1996) and circumsporozoite protein (CSP) (Greenwood, Willis, & Perham, 
1991; Monette, Opella, Greenwood, Willis, & Perham, 2001; Willis, Perham, & 
Wraith, 1993). These studies have used a combination of phage display of 
random peptide libraries, gene fragment libraries, crystal structure studies along 
with peptide immunizations to determine mimotopes and eventually epitopes on 
these antigens.  
Previously, we generated and immunologically characterized a panel of 
anti-DBPII murine mAbs. Some of these monoclonal antibodies were broadly 
inhibitory like mAbs 3C9, 2D10, 2C6 and 2H2 while mAb 3D10 was highly 
reactive but still a poor inhibitor to DBPII-erythrocyte binding in a standard in vitro 
COS 7 cell assay (Ntumngia et al., 2012b). With the exception of mAb 3D10, all 
the mAbs specifically recognized only conformational dependent epitopes on 
recombinant DBPII. Crystallography studies reveal that DBPII is largely alpha-
helical and may be assigned into three sub-domains delineated by six disulphide 
bonds (Batchelor et al., 2011). Using phage display we have previously shown 
that, each of the sub-domains or natural combinations of the sub-domains of 
DBPII have varying patterns of affinity to these mAbs (Siddiqui et al., 2012). 
These data suggest that identifying the epitopes of these inhibitory and non-
inhibitory mAbs will help design a strain-transcending subunit vaccine.  
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In this study, we further map the epitopes of these anti-DBPII mAbs by 
screening DBPII gene fragment libraries expressed on M13 phage surface for 
minimal reactive peptide fragments. DBPII epitopes identified for the broadly 
inhibitory anti-DBPII mAb 3C9 and non-inhibitory mAb 3D10, conjugated to 
carrier protein KLH, were used to produce an antibody immune response in 
BLAB/c mice. Anti-3C9 epitope but not anti-3D10 epitope antibodies inhibited 
DBPII-erythrocyte binding. Site directed mutagenesis was further carried out to 
determine essential residues within the epitope. The information derived from this 
study contributes to our understanding of the specific targets for vaccine-elicited 
protective immunity. In particular, this study demonstrates an approach that may 
be successful in boosting antibody responses targeted against conserved 
protective epitopes, with functional inhibition against broader allelic variants and 
diverse P. vivax strains. 
 
MATERIALS AND METHODS 
 
Generation of phage displayed DBPII gene fragment libraries  
The full-length PCR product (20 µg) from DBPII Sal1 and 7.18 haplotypes 
were digested with DNase I at 5 U/ml. The resulting fragments were purified by 
sodium acetate precipitation and ragged ends blunted with a Vent polymerase 
(NEB). The pHENH6 vector was digested with PstI (NEB) and also blunted with 
Vent polymerase. The resulting products from the randomly fragmented DBPII 
were cloned into the treated pHEN-H6 vector and then into TG1 E. coli by 
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electroporation. The distribution of the fragments in the library was determined by 
PCR and sequencing of forty random clones. The distribution of the fragments in 
the library were determined by PCR and sequencing of forty random clones. The 
library was then grown in 20mls of 2xTryptone-yeast extract media containing 50 
µg/ml of ampicillin at 37°C, shaking until OD 600 nm. 1x1011PFU of M13K07 
helper phage was added and cultured for an extra 1 h at 37°C without shaking to 
allow infection. The entire culture was then transferred into 400 ml of super broth, 
containing 70 µg/ml kanamycin and 50 µg/ml ampicillin, and incubated at 37°C 
with shaking overnight. The bacteria was pelleted by centrifugation at 8,000 X g 
for 15 min and the phage precipitated from the supernatant with PEG-NaCl as 
described (Adda, Tilley, Anders, & Foley, 1999; Coley et al., 2006). The phage 
was resuspended in 1 ml of PBS and used subsequently or stored at -80°C.  
 
 Panning of phage displayed DBPII gene fragment library  
Affinity panning of DBPII Sal1 gene fragment to anti-DBPII mAbs 3D10, 
3C9, 2D10, 2C6 and 2D10 was carried out as described previously (Coley et al., 
2001). Briefly, 10 wells of Maxisorp-Nunc ELISA plate were coated over night at 
4°C with 100 µl per well of test mAb at a final concentration of 2.5 µg/ml diluted in 
PBS. Plates were washed twice with PBS and unbound surfaces blocked with 
200 µl of 5% skimmed milk in PBS for 2 h at room temperature. After another 
round of washing, approximately 1x1011 phage/ well in 1% skimmed milk in PBS 
were added to wells and incubated for 1 h at room temperature. Non-adherent 
phage particles were washed off twice with PBS/0.05% Tween-20. The bound 
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phage was eluted with 100 µl of 0.1M Glycine, pH 2.2 and immediately added to 
10 ml of log phase E. coli TG1 cells and cultured for 30 mins at 37°C for infection 
to occur. Ampicillin was added to 50 µg/ml and the culture and incubated for 
another 30 mins at 37°C before addition of the M13 helper phage and then 
incubated for another 1 h at 37°C. The culture was then transferred to a 200 ml 
super broth containing 50 µg/ml of ampicillin and 70 µg/ml of kanamycin and 
incubated at 37°C overnight with shaking at 200 rpm. The phage was harvested 
as described above and another round of panning carried out for a total of up to 
four panning cycles per antibody. Ten clones from each round of panning were 
selected, their inserts amplified by PCR and sequenced to determine the identity 
of the fragments of DBPII that binds to each mAb.  
  
Panning a random peptide library on mAb-3D10 
Panning on mAb 3D10 was performed using a random 20mer peptide 
library (Courtesy of Foley M and Anders RF, La Trobe University, Australia) as 
described (Adda et al., 1999; Coley et al., 2001). Briefly, phage peptide library at 
1011 phage/well was incubated with mAb 3D10 coated wells for 1 h at room 
temperature. Eluted phage was allowed to re-infect K91 E. coli grown to log 
phase in 10 ml Tryptone-yeast extract media at 37°C for 1 h and then grown 
overnight in 200 mls of super broth with 40 µg/ml of tetracycline. Phage was 
harvested and further rounds of panning carried out as described above. Clones 
isolated from round 3 were sequenced to determine the peptide sequences. 
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ELISA of phage displayed rounds of panning 
Enrichment ELISA was performed as described (Coley et al., 2001). 
Briefly, 100 µl of anti-DBP mAbs antibodies at 2.5 µg/ml in PBS were coated on 
to wells of 96-well microtiter plates (Maxisorp-Nunc) overnight at 4°C. Anti-
PfAMA1 specific, mAb-1F9 or 5G8 (Coley et al., 2001) was coated on each plate 
as negative control antibody. The plates were washed twice with PBS 
0.05%Tween-20 and blocked for 2 h at room temperature with 200 µl/well of 10% 
skimmed milk diluted in wash buffer. After three washes, phage diluted in 
PBS/1% milk to 1x1011 pfu/ml was added in triplicates and incubated for 2 hours 
at room temperature. Plates were washed four times and the wells were 
incubated with HRP-conjugated anti-M13 mAb (GE Life Sciences) for 1 h at room 
temperature. The plates were then washed five times and bound phage detected 
by incubating wells with 100 µl of H2O2 activated TMB substrate (Sigma). The 
reaction was stopped with 100 µl 2 N H2SO4 and plates were read at 450 nm 
absorbance.  
 
Immunoblots  
Approximately 1X1012 phage particles were boiled in SDS-PAGE sample 
buffer for 3 min and separated by SDS-PAGE and electrophoretically transferred 
on to nitrocellulose membrane. The membrane was blocked overnight in 10% 
skimmed milk diluted in PBS/Tween-20. The membrane was probed with anti-
DBPII mAb, washed with PBS/Tween-20 before incubating with an HRP-
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conjugated anti-mouse secondary antibody. The bound antibody was detected by 
enhanced chemiluminescence (ECL) substrate  (Amersham). 
 
Immunizations 
Peptides corresponding to sequences of the epitopes identified from 
panning on the gene fragment library and mimotopes from panning on the 
random peptide were synthesized and conjugated to keyhole limpet hemocyanin 
(KLH) using Maleimide-Activated mcKLH (ThermoScientific 77611) according to 
the manufacturer’s specifications. The following 6 peptides were produced 
commercially (Pacific Immunology): 3C9 epitope peptide (3C9-e1) from DBPII 
sub-domain 3; 3D10 epitope peptide (3D10-e1) from DBPII sub-domain 1; 3D10 
mimotope 1; (3D10-m1) ; 3D10 mimotope 2: (3D1-m2); 3D10 mimotope 3: 
(3D10-m3) and a control peptide.  
The conjugated peptides were used to immunize 6-8wks old Balb/c mice 
(Harlan) to raise immune sera. All animals were handled in compliance with 
approved IACUC protocol and good animal practice. Briefly, mice in all groups, 
(n=10) were bled for pre-immune sera and each immunized thrice at three week 
intervals with 5 µg of peptide conjugated to KLH emulsified in Titermax Gold 
adjuvant. Each animal received a 50 µl antigen-adjuvant mix administered 
subcutaneously at the base of the tail. Mice immunized with KLH and adjuvant 
alone served as control. All mice were bled for final serum four weeks after the 
second boost. 
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Measurement of antibody titers 
Total anti-peptide IgG titers in the serum of each group was evaluated by 
end point titration ELISA against and to recombinant DBPII Sal1 and peptide 
conjugated to bovine serum albumin (BSA). Imject™ Maleimide-Activated BSA 
Spin Kit (ThermoScientific 77667) was used as specified by manufacturer to 
conjugate the peptides. ELISAs were carried out as described previously 
(Ntumngia et al., 2012b), 0.1 µg of peptide conjugated to BSA or 0.25 µg of 
recombinant antigen were coated per well of a microtiter plate over night and 
blocked with 5% skimmed milk PBS/0.05% Tween 20 detected by 3-fold dilution 
of mouse sera was used starting at 1:200. Bound antibodies were detected using 
alkaline phosphatase-conjugated anti-mouse antibody (Kirkegaard & Perry 
Laboratories). Pre-immune serum, at the lowest dilution, served as background 
and was subtracted.  
 
Measurement of functional inhibition of DBP-Erythrocyte binding 
Pooled immune serum from each group of mice that recognized rDBPII 
Sal1 by ELISA was tested further for inhibition of DBPII-erythrocyte binding by a 
modified version of the standard in vitro COS7 cell assay (Chitnis & Miller, 1994; 
P. Michon et al., 2000). A panel of naturally occurring DBPII alleles were 
transiently expressed on the surface of transfected COS7 cells as previously 
described (Ntumngia et al., 2013). Cells were pre-incubated with triple-fold 
dilution (starting at 1:50) of pooled group sera 42 h post transfection, followed by 
incubation with human Duffy positive erythrocytes. Inhibition of binding by each 
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serum was calculated as a percentage of Duffy positive erythrocyte binding in 
immune versus corresponding pre-immune serum control incubated on every 
plate (Ntumngia et al., 2013).   
 
Immunofluorescence assay of COS7-surface expressed DBPII 
A few DBPII constructs with single and multiple residue mutations, in 
epitope residues, were produced (GenScript) on pEGFP vector used for DBPII 
expression on COS7 cells. COS7 cells transfected with different mutated DBPII 
transgenes, were incubated on cover slips in 24 well plates for 42 hr (Chitnis & 
Miller, 1994). The cells were then fixed with PBS/2% formaldehyde for 15 min, 
washed with PBS and incubated at room temperature with 5 µg/ml of anti-DBPII 
mAbs 3C9, 3D10 and 2D10 and anti-AMA1 mAb 1F9, as a negative control, for 
90 min. After PBS wash, the cells were incubated with rhodamine-conjugated 
goat anti-mouse secondary antibody (KPL) in PBS/0.1%BSA for 30 min in the 
dark. The cells were washed with PBS and nuclear stain Hoechst at 1:1000 
dilution for 15 mins in the dark. After the final wash, the cells on the coverslip was 
fixed onto a glass slide with flurophoreG and stored at -20°C until ready to be 
observed using a fluorescence microscope. Zeiss microscope was used to 
capture images of 10 cells at 40X magnification for each DBPII-antibody pair at 
constant exposure time of 88ms for blue channel, 513ms for green channel and 
2049ms for red channel. Relative fluorescence unit (RFU) across a cell from end 
to end was collected. The highest 50 points for the red channel for each cell was 
used to normalize for the size of cells. The sum of the highest 50 points for 10 
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cells was used to determine the mean RFU for each DBPII-antibody pair. The 
mean RFU of DBPII mutants were compared with wild type DBPII Sal1 for the 
respective antibody.  
 
RESULTS 
The phagemid vector pHENH6 was used to be express DBPII as a 
chimera, fused with a C-terminal c-myc epitope tag and the pIII minor coat 
protein on the surface of the engineered pHENH6 phage (Fig.2.1). The variable 
length DBPII fragments came from a gene fragment library of random length 
PvDBP coding constructed by DNAseI-digesting DNA encoding DBPII sequences 
(Fig. 2.2 and 2.3). Recombinant phagemid libraries for Sal1 and 7.18 that were 
estimated to have 7 x 105 pfu/µg and 4.6 x 106 pfu/µg of plasmid DNA gene 
fragments. Sequencing of 40 random clones of each library revealed that the 
fragments in the library spanned the entire coding sequence and no bias towards 
any particular region was observed (Fig. 2.4); however, as expected most of the 
fragments were ligated out of frame or in the incorrect orientation. Phage stocks 
generated from the gene fragment libraries were biopanned on mAbs 3D10, 3C9, 
2D10, 2C6 and 2H2 to enrich for high affinity binders to each of these antibodies.  
Affinity selection of reactive phage to the target antibody was carried out 
through the sequential rounds of panning by standard procedures. ELISAs were 
carried out with positive control mAb 9E10 to standardize library titer in each 
round of panning, while an anti-PfAMA1 antibody, mAb 1F9, served as a 
negative control (Figs. 2.5 – 2.9 A and B). Panning on mAb 3D10 selected for 
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phage clones that bound well to mAb 3D10, but poorly to mAbs 3C9 and 1F9 for 
both gene fragment libraries (Fig. 2.5 A and B). In contrast, panning on mAb 3C9 
selected for phage clones from both gene fragment libraries that bound well to 
mAb 3C9 and poorly to mAbs 3D10 and 1F9 (Fig. 2.6 A and B). Likewise 
panning on mAb 2D10 (Fig 2.7 A and B), mAb 2C6 (Fig 2.8 A and B) and mAb 
2H2 (Fig 2.9 A and B) isolated phage clones that bound well to their respective 
target antibody but bound poorly to mAbs 1F9 and 3D10 for both gene fragment 
libraries. Phage clones isolated from panning on all the antibodies bound well to 
mAb 9E10, suggesting that the procedure had enriched for clones possessing 
DBPII coding sequence in-frame and in the correct-orientation.   
Sequence analysis of 10 clones from each round of panning was used to 
identify the length and specificity of DBPII CDS inserts. Clones from the last 
rounds of panning tended to have inserts of similar sizes while those of the early 
rounds tended to be more variable. Sequencing results further showed that only 
clones in the last round of panning were in frame and in the right orientation, 
corroborating ELISA results. Ten clones from the last rounds of panning on mAb 
3D10, had overlapping fragments of sub-domain 1 of DBPII in-frame and in the 
correct orientation (Fig. 2.5 C and D). Most clones from the last rounds of 
panning on mAb 3C9 were comprised of overlapping fragments of sub-domain 3 
(Fig. 2.6 C and D). However clones from the last rounds of panning on mAb 
2D10 (Fig. 2.7 C and D), mAb 2C6 (Fig. 2.8 C and D) and mAb 2H2 (Fig. 2.9 C 
and D) had a fragment that comprised of almost all of sub-domain 3. 
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Phage were cultured from two clones enriched for during round 3 panning 
on mAb 3D10 and three clones enriched for during round 3 panning on mAb 
3C9. Each phage clone was tested for reactivity to the selecting mAb by ELISA 
and Western Blot (Fig. 2.10). Results from both assays indicated that mAb 3D10 
phage clones bound specifically to mAb 3D10 (Fig. 2.10 A and C). Similarly, mAb 
3C9 phage clones were found to bind specifically to mAb 3C9 (Fig. 2.10 B and 
D). The observed specificity suggested that the isolated phage clones displayed 
the minimal fragments of DBPII needed for the mAbs to bind their respective 
epitopes.  
To further characterize the linear epitope for mAb 3D10, a random 20mer 
peptide library termed Adlib1 (courtesy of Adalta Pty Ltd.) was also used to pan 
on the antibody. After 3 rounds of biopanning using the approach outlined in 
Figure 2.1 B, the level of reactivity enrichment was assessed by ELISA. Figure 
2.11 shows that phage from rounds 1, 2 and 3 react well with mAb 3D10 (black) 
and relatively poorly to the negative isotype control anti AMA1 mAb 5G8 (white).  
Individual clones from round 3 were sequenced. From 10 clones, 4 sequences 
were identified, each containing what may be a degenerate sequence motif 
(highlighted in bold underline). An apparent key feature within the 3D10 epitope 
is a hydrophilic 3-residue motif YK(R/Y/E). Although the Adlib1 peptide library is 
unrelated to DBPII, YKR is present in the DBPII sequence in the 22 amino acid 
region of sub-domain 1 that was selected for by the gene fragment library.  
Further characterization to determine the potential immunogenicity of the 
minimal epitopes was pursued next.  The minimal peptides identified from 
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panning with DBPII gene fragment libraries and the random peptide library were 
produced synthetically and conjugated to KLH carrier protein to produce 
immunize mice (Table 1). Following two boosts, ELISAs were carried out to 
determine reactivity of the anti-peptide sera for the minimal peptide epitopes of 
3D10 and 3C9. Serum from each mouse was tested for affinity to its 
corresponding peptide. All peptides, with the exception of the 3D10 epitope 
peptide, were immunogenic. Further, the serum from each mouse was tested for 
affinity to rDBPII, by ELISA. Only mice immunized with 3C9 epitope peptide 
produced an immune response that recognized rDBPII (Fig 2.13 A). 
 To assess anti-3C9 epitope peptide sera for its potential to inhibit DBPII-
erythrocyte binding, a standard in vitro COS7 binding inhibition assay was carried 
out (Fig 2.13 B). A concentration-dependent inhibition of binding of DBPII-
erythrocytes was observed. Serum dilution that correspond to 50% inhibition 
(IC50) of binding of erythrocytes to the DBPII alleles were 1:313.6 for Sal1, 
1:309.1 for 7.18, 1:171.6 for AH and 1:52.73 for P.  Binding inhibition curves of 
each allele was compared to Sal1 using Dunnett’s multiple comparison test. 
Alleles 7.18 and AH showed no significant difference compared to Sal1, 
suggesting that 3C9-e1 produced and antibody response that recognizes a 
conserved region of DBPII within these alleles.  
Site directed mutagenesis was performed to substitute residues of the 
epitopes that were identified through biopanning (Fig 2.14).  These residues are 
predicted to be surface exposed and reactive with the mAb.  The purpose of this 
procedure was to validate the relative importance each residue within the epitope 
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may have in antibody binding. Immunofluorescence assay were performed to 
determine the ability of the antibodies to bind to DBPII mutated at specific 
residues expressed on the surface of COS7 cells. The relative fluorescence unit 
(RFU) was used to compare binding of antibody to wild type DBPII Sal1 and 
mutant. 
Mutation of a single residue E538A (M20) within the 3C9 epitope 
remarkably reduced binding of mAb 3C9 compared to DBPII Sal1 (Fig 2.15 A). 
Mutant 6, Y445A/V446A/F530A/F535A  (M6) also showed reduction in binding to 
mAb 3C9. Structurally, residues E538 and F535, on the epitope, seem to interact 
with residues Y445 upstream to the epitope but still in subdomain3 (Fig 2.16 A 
and 2.17 C). It is interesting to note that the single mutation of F535  (Mutant 19) 
had almost no difference in binding to mAb 3C9 compared to DBPII Sal1 and yet 
this mutation greatly reduced binding to mAb 2D10 (Fig 2.15 B). A similar effect 
is observed with the single amino acid substitution E529A (Mutant 14), which 
greatly reduced binding to mAb 2D10 but no effect on mAb 3C9 binding. 
Structurally, V446 seems to interact with G442 which when mutated also showed 
reduction in binding (Mutant 4) to mAb 2D10 and not to mAb 3C9 (Fig 2.16 B and 
2.17 D).  Multiple mutations to residues Y445A, V446A, F530A and F535A 
(Mutant 6) reduced binding to both mAb 3C9 and mAb 2D10. 
 
DISCUSSION  
Plasmodium vivax DBP is vital for merozoite invasion of Duffy positive 
reticulocytes making it the foremost vaccine candidate against blood stage vivax 
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malaria (Miller et al., 1976). PvDBP is a member of the Duffy-binding-like 
erythrocyte binding proteins (DBL-EBPs) family (Adams et al., 1992) that 
includes P. falciparum EBA175, PfEBL1, P. knowlesi DBPα,β and γ among 
others (Adams et al., 2001). Studies of DBP have historically helped to define our 
understanding of the important biological properties of this important family of 
malaria parasite ligands. The N-terminal cysteine rich region is the ligand domain 
known as the DBL domain or DBP region II in P. vivax that is essential of 
receptor recognition (Adams et al., 1992; Chitnis & Miller, 1994). Intergenic 
variation in this region is important for altering receptor specificity while intragenic 
or allelic variation of the ligand domain alters antigenic character. DBP allelic 
variation is mainly constrained to polymorphisms in the DBL domain and varies 
by geographic region (Hwang, Kim, & Kho, 2009; Ju et al., 2012; Premaratne, 
Aravinda, Escalante, & Udagama, 2011). Some polymorphic residues on DBPII 
are unique to a certain geographical region while others are common among 
global vivax alleles, like residues K371E, D384G, E385K, K386N, N417K, L424I, 
W437R and I503K (Babaeekho, Zakeri, & Djadid, 2009; Hwang et al., 2009; Ju et 
al., 2013; Ju et al., 2012). Generally, variation occurs in non essential residues 
flanking residues critical for receptor recognition while variation in some residues 
is more important than in others.  For example, residues 417, 437 and 503 were 
identified as critical determinants of antigenic character, since altering these 
residues conferred a significant change in sensitivity to inhibitory anti-DBP 
antibodies (VanBuskirk, Cole-Tobian, et al., 2004).  Overall evidence indicates 
that variation plays an important role in strain-specific immunity to DBP. 
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DBPII is largely alpha-helical and may be assigned into three sub-domains 
delineated by six disulphide bonds. While sub-domain1 of DBPII is made up of 
an antiparallel beta-hairpin, sub-domains 2 and 3 are seen as distinct bundles of 
three alpha-helixes (Batchelor et al., 2011).	  	  NMR studies of PvDBPII in contact 
with the core region of DARC ectodomain revealed that dimerization of DBPII is 
required for and driven by receptor engagement as DARC ectodomain form a 
helix that binds to the dimer interface (Batchelor et al., 2014). Human anti-DBP 
inhibitory antibodies have been shown to bind to sub-domain 2 in a surface 
region adjacent to the dimer interface (Batchelor et al., 2014; Chootong et al., 
2010). Given that these dominant Bc epitopes are at the dimer interface are not 
part of residues critical for either dimerization of receptor binding, anti-DBP 
immune efficacy appears to be primarily mediated through steric hindrance of 
dimerization. 
Naturally acquired immunity to DBPII is present in P. vivax endemic areas, 
anti-DBPII immune response tends to increase with age and exposure (Chootong 
et al., 2010; J. L. Cole-Tobian et al., 2002; Grimberg et al., 2007; VanBuskirk, 
Cole-Tobian, et al., 2004; Xainli et al., 2003). Studies have shown that about 8-
10% of P. vivax-exposed individuals produce high titer strain-transcending or 
broadly neutralizing antibodies (King et al., 2008), associated with 50% reduction 
in risk of infection with P. vivax (Chootong et al., 2010; King et al., 2008). 
Concurrently, the antibody responses to DBP seen in people living in P. vivax 
endemic areas and the elevated levels of amino acid sequence polymorphisms 
are consistent with the hypothesis that the molecule is under immune selective 
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pressure, especially as the DBP polymorphisms are concentrated in the ligand 
domain region II, which has a nucleotide substitution rate four times higher than 
the rest of the molecule (Ampudia et al., 1996; J. L. Cole-Tobian et al., 2002; 
Fraser et al., 1997; P. A. Michon et al., 1998; Tsuboi et al., 1994). In previous 
studies we have identified epitopes reactive with polyclonal human immune 
antibodies using an array of overlapping linear peptides attached to plastic pins.  
This methodology proved to be surprisingly robust in identifying conformational 
epitopes, especially the dominant Bc epitope.  This epitope termed “DEK” for its 
first three amino acids was confirmed subsequently to be a major target of 
naturally occurring human immune antibodies and a major determinant for 
controlling strain specific immunity elicited by vaccination (Ntumngia & Adams, 
2012; Ntumngia et al., 2013). The current study sought to identify specific epitope 
targets of mAbs induced by vaccination in mice, using phage display technology. 
Phage display technology is a great tool for elucidating the molecular 
nature of protein-protein interactions (Coley et al., 2001; Smith, 1985; Wilson & 
Finlay, 1998) and we have established the methodology for DBPII. Recombinant 
filamentous phage was engineered to display DBPII (Sal1 and 7.18 alleles) on its 
surface as part of the pIII capsid protein. Selective panning of recombinant phage 
libraries on antibodies was used to isolate target epitopes or peptide mimics. 
Positive epitope-containing clones reactive with the anti-DBPII inhibitory 
antibodies were enriched by successive panning assays. The sequence identity 
of the selected peptides was determined by DNA sequencing. The identified 
recombinant fragments and peptides represent epitope-specific reagents that 
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were used to evaluate reactivity of epitope-specific antibodies. A surprising 
outcome in this study is the discovery that Bc epitope targets of highly inhibitory 
anti-DBP are located in subdomain III away from the dimer interface and 
residues determined to be critical for erythrocyte binding. Only minimal epitope 
target of an inhibitory antibody could be defined whereas the minimal target of 
most inhibitory mAbs was the entire subdomain III (Fig 6, 7 and 8).  In contrast 
the minimal epitope of the non-inhibitory mAb 3D10 was located in a surface 
region of subdomain I closer to the dimer interface.   
Site directed mutagenesis studies revealed that binding inhibitory mAbs 
3C9 and 2D10 are both sensitive to disruption of Y445, V446, F530 and F535 
pocket present on the surface of sub-domain 3. Although F530 and F535 make 
up part of the 3C9 epitope identified using phage displaying DBPII gene fragment 
library, single amino acid mutation of these residues did not disrupt binding of 
3C9. This suggests that there is some synergistic interaction of these aromatic 
residues that make up the 3C9 and 2D10 binding pocket on DBPII. E538 seems 
to have polar interactions with F535 in the epitope and Y445 in the neighboring 
helix, which seems to be more important for binding of mAb 3C9 than mAb 2D10. 
However, V446 seems to interact with G442, which is more important for binding 
of mAb 2D10 than mAb 3C9. 
The 3C9 minimal peptide epitope was further characterized by vaccination 
studies to determine its potential as a subunit synthetic vaccine.  The 
immunogenicity of the ‘protective’ 3C9 epitope was compared to the minimal 
peptide epitope of 3D10.  Although 3D10 represented the highest titer mAb within 
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the anti-DBP panel created, and was reacted equally to all DBP alleles tested by 
ELISA, it has virtually no ability to block DBPII to erythrocytes (Ntumngia et al., 
2012a).  
Various studies have examined the functional efficacy of vaccine-induced 
anti-DBP antibodies to block DBP erythrocyte binding or inhibition of merozoite 
invasion of erythrocyte (Arevalo-Herrera et al., 2005; Devi et al., 2007; Grimberg 
et al., 2007; Ntumngia et al., 2013). As a general rule properly refolded 
recombinant rDBPII that is capable of erythrocyte binding activity is required for 
induction of inhibitory anti-DBPII antibodies.  Indeed the epitope targets of the 
protective mAb 3C9 (conformational) and non-protective mAb 3D10 (partially 
linear) are consistent with this observation. In our approach the DBP peptide 
immunogens, consisting of the synthetic linear peptides of the 3C9 or 3D10 
epitopes were conjugated to carrier KLH, were used to immunize mice.  The 
3D10 immunogens included mimotope peptides of epitope targets isolated from a 
random peptide library. Surprisingly, we found that a 3C9 epitope peptide 
successfully induced an antibody response reactive to the immunizing peptide, 
the refolded peptide as well as inhibitory to DBPII erythrocyte binding.  This result 
suggests that the 3C9 linear peptide has some inherent structural tendency to 
assume its 3D conformation displayed on the surface of native DBP and is the 
target of inhibitory antibody. Peptides like 3C9 epitope peptide, capable of 
eliciting protective antibodies, may be critical for the design of a sub-unit vaccine 
against asexual blood stage vivax malaria. 
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TABLES AND FIGURES 
 
 
Figure 2.1: Schematic of the different components of phage display system and 
biopanning for epitope mapping 
 
 
Figure 2.2: Schematic of the construction of DBPII gene fragment library 
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Figure 2.3: DNA gels of pHEN-H6 vector and insert DBPII Sal1 and 7.18 
digested to make up gene fragment library. (A) pHEN-H6 vector seen in lane 2 
was digested with PstI restriction enzyme seen in lane 3 (B) Small scale digest of 
DBPII Sal1 with DNAseI was carried out to determine DNAseI concentration to 
obtain the most broad spread of fragments. (C) Lane 3 shows DBPII Sal1 and 
lane 4 shows DBPII Sal1 DNAseI digested (D) Lane 2 shows DBPII 7.18 and 
lane 3 shows DBPII 7.18 DNAseI digested. The digested vector and gene 
fragments were blunt-ended with Vent polymerase and ligated before being 
electroporated into TG1 E. coli. 
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Figure 2.4: Schematic of sequences generated from DBPII Sal1 & 7.18 gene 
fragment libraries. Sequencing of PCR products generated by screening 40 
individual clones revealed that the gene fragments in the library spanned the 
entire coding sequence, with no bias towards any particular region.  The different 
colours represent the lengths of the various gene fragments generated. 
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Figure 2.5: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning 
on mAb 3D10. ELISA showing reactivity of phage clones enriched by successive 
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII 
7.18. A pool of phage from each round of panning was tested for binding to anti-
DBPII mAbs 3D10, 3C9 and the anti-c-myc epitope tag antibody mAb-9E10. The 
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars 
represent mean OD of triplicate wells and error bars indicate ±SD. Individual 
clones (n=10) from the last round of panning with each of the libraries were PCR 
amplified and sequenced. The positions of the various peptides identified are 
indicated in (C) and (D) for mAbs 3D10. The  degenerate sequence identified 
from the phage clones by panning on each on the antibodies is shown. 
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Figure 2.6: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning 
on mAb 3C9. ELISA showing reactivity of phage clones enriched by successive 
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII 
7.18. A pool of phage from each round of panning was tested for binding to anti-
DBPII mAbs 3C9, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The 
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars 
represent mean OD of triplicate wells and error bars indicate ±SD. Individual 
clones (n=10) from the last round of panning with each of the libraries were PCR 
amplified and sequenced. The positions of the various peptides identified are 
indicated in (C) and (D) for mAbs 3C9. The  degenerate sequence identified from 
the phage clones by panning on each on the antibodies is shown. 
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Figure 2.7: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning 
on mAb 2D10. ELISA showing reactivity of phage clones enriched by successive 
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII 
7.18. A pool of phage from each round of panning was tested for binding to anti-
DBPII mAbs 2D10, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. 
The PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars 
represent mean OD of triplicate wells and error bars indicate ±SD. Individual 
clones (n=10) from the last round of panning with each of the libraries were PCR 
amplified and sequenced. The positions of the various peptides identified are 
indicated in (C) and (D) for mAbs 2D10. 
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Figure 2.8: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning 
on mAb 2C6. ELISA showing reactivity of phage clones enriched by successive 
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII 
7.18. A pool of phage from each round of panning was tested for binding to anti-
DBPII mAbs 2C6, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The 
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars 
represent mean OD of triplicate wells and error bars indicate ±SD. Individual 
clones (n=10) from the last round of panning with each of the libraries were PCR 
amplified and sequenced. The positions of the various peptides identified are 
indicated in (C) and (D) for mAbs 2C6. 
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Figure 2.9: Gene fragments of DBPII Sal1 and 7.18 selected through biopanning 
on mAb 2H2. ELISA showing reactivity of phage clones enriched by successive 
panning on mAb-3D10 with gene fragment library (A) DBPII Sal1 and (B) DBPII 
7.18. A pool of phage from each round of panning was tested for binding to anti-
DBPII mAbs 2H2, 3D10 and the anti-c-myc epitope tag antibody mAb-9E10. The 
PfAMA1 specific mAb-1F9 served as a negative control antibody. The bars 
represent mean OD of triplicate wells and error bars indicate ±SD. Individual 
clones (n=10) from the last round of panning with each of the libraries were PCR 
amplified and sequenced. The positions of the various peptides identified are 
indicated in (C) and (D) for mAbs 2H2. 
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Figure 2.10: Specificity of isolated phage clones with mAb-3D10 and 3C9. Phage 
clones identified from round 3 biopanning on mAb 3D10 (C4 and C5) and mAb 
3C9 (C4, C6, C9) as well as phage clones expressing sub-domain 1 (sd1) and 
sub-domain 3 (sd3) fragments of DBPII were tested for cross reactivity with the 
homologous and heterologous antibodies by ELISA (A and B) and immunoblot 
analysis (C and D). mAb-3D10 binds specifically to clones C4 and C5 and the 
sd1 expressing clones, while  mAb-3C9 binds only to mAb-3C9 isolated clones 
and sd3 expressing clones. mAb-1F9 is a non-specific anti-DBPII antibody used 
as negative control and mAb-9E10 is specific to the c-myc epitope of the 
phagemid. Each bar represents the mean OD450 of triplicate wells and error bars 
represent ±SD. 
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Figure 2.11: Panning a random peptide on mAb-3D10. (a) ELISA showing 
reactivity of phage clones from rounds of panning on mAb-3D10. mAb-5G8 
served as a negative control antibody, while a mAb-5G8 positive binding phage 
clone (Pos C) served as a positive control. The bars represent mean of triplicate 
wells while the error bars represent ±SD. (b) Alignment of a sequence of the 
mAb-3D10 binding epitope on sd1 of DBPII (top) and sequences of three 
mimotopes (M1, M2 and M3) from random peptide library with affinity for mAb-
3D10. the underlined residues show a three amino acid motif common to the 
DBPII epitope and the sequences from the mimotopes isolated form the random 
peptide library. 
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Figure 2.12: Putative epitopes of mAbs 3C9 and 3D10. Crystal structure of DBPII 
dimer with sub-domains 1 (in green), 2 (in tan) and 3 (in light blue). Putative 
epitope of inhibitory mAb 3C9 (in red) is on sub-domain 3 while putative epitope 
of non-inhibitory mAb 3D10 (in navy blue) is on sub-domain 1. The two views 
represent the front and back of the ligand for the surface model (top) and for 
secondary structure cartoon (bottom). 
 
 
Table 2.1: Peptides identified through biopanning used for immunizations. 
 
Peptides were conjugated to KLH and used to immunize groups of ten BALB/c 
mice. Following two boosts sera was collected. Sera was tested for antibodies to 
corresponding peptides and to rDBPII Sal1 by ELISA. 
 
Putative Epitope 
of mAb 3C9 
Putative Epitope 
of mAb 3D10 
Sub$Domain+1+ Sub$Domain+2+ Sub$Domain+3+
00 1800 
Peptide rDBPII+Sal1
3C9$e1 DILKQELDEFNEVAFENE + +
3D10$e2 IINHAFLQNTVMKNCNYKRKRR + 1
3D10$m1 VGNLDFSRFHKSSLDYKRGQ + 1
3D10$m2 VKFTDRYKYSSMKGYARQGR + 1
3D10$m3 KINMYKEVRTRQLSVRPSPE + 1
Control TPDERYRELDSHAQNESC + 1
ELISA+with+
Name Peptide+Sequence
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Figure 2.13: Anti 3C9-e1 sera characterization. (A) Mice immunized with 3C9-e1 
produced an antibody response that recognized rDBPII by ELISA. The numbers 
for each curve correspond to sera from a mouse. Each point on the curve 
represent mean OD of triplicate wells and error bars indicate ±SD. (B) Pooled 
group sera was used to test for erythrocyte-DBPII binding inhibition by in vitro 
COS7 assay. The curves correspond to the different alleles of DBPII that were 
tested. Each point on the curve represent percent inhibition of two experiments 
each with triplicate wells and error bars indicate ±SD. 
 
 
 
Figure 2.14: Amino acid sequence alignment of DBPII Sal1 to mutants. Site 
directed mutagenesis of DBPII Sal1 with alanine substitutions at specific sites 
depicted in red. 
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Figure 2.15: Immunofluorescent assay of DBPII mutants expressed on COS7 
cells. Fluorescence images of 10 cells for each DBPII-antibody pair was 
captured. Mean pixel intensity for each DBPII-antibody pair was determined. 
Each bar represents mean pixel intensity compared to DBPII Sal1 and error bars 
indicate ±SD. 
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Figure 2.16: Crystallographic representation of residues on DBPII important for 
antibody binding. (A) Residues important for binding to mAb 3C9, in red single 
substitution of mutant 20 and in blue multiple substitutions of mutant 6. (B) 
Residues important for binding to mAb 2D10, in blue multiple substitutions of 
mutant 6, in red single substitution of mutant 19 (also a part of mutant 6), single 
substitution of mutant 4 and 14 in green and purple. 
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Figure 2.17: Crystallographic representation of putative mAbs 3C9 and 2D10 
binding sites on DBPII. (A) Cartoon representation of DBPII monomer in yellow 
and 3C9 epitope in blue. (B) Cartoon representation of 3C9 epitope with residue 
side chains as line representation. (C) Polar interactions in green that seem 
important for mAb 3C9 binding. (D) Polar interactions in green that seem 
important for mAb 2D10 binding. 
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CHAPTER THREE: 
RANDOMIZED HELICAL SCAFFOLD AFFIBODY LIBRARY TO MAP 
CONFORMATIONAL EPITOPES ON PLASMODIUM VIVAX DUFFY BINDING 
PROTEIN 
 
ABSTRACT 
Plasmodium vivax Duffy binding protein (DBP) is an essential ligand for 
reticulocyte invasion making it a premier asexual blood stage vaccine candidate. 
However, as DBP is highly polymorphic in its ligand domain and prone to elicit an 
immune response that is strain specific. Vaccine design studies have mapped Bc 
epitope targets of inhibitory and non-inhibitory antibodies to characterize 
conserved epitopes that could be used to over come the challenges of allelic 
variation. Since DBP region II is mostly made up of alpha-helices, we used a 
randomized helical scaffold library, the Affibody library, displayed on M13 phage, 
to determine conformational epitopes. Affibody libraries, an engineered affinity 
protein scaffold have been previously used to select for high affinity binders to 
receptors or enzymes. The novelty of this study is in the use of this randomized 
helical scaffold library to display conformational epitopes.  
 
INTRODUCTION 
Plasmodium vivax has the widest geographical distribution and is the 
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second most prevalent of the five Plasmodium species that cause malaria in 
humans ("World Malaria Report 2014," 2014). Although historically called ‘benign 
tertian malaria’ because it is less virulent than P. falciparum (Garnham, 1951), 
when trying to eliminate malaria, P. vivax is often the ‘last parasite standing’ 
(Tatem et al., 2010), Complicating elimination of vivax malaria is the added 
obstacle of reactivation or relapse of active blood-stage infections from dormant 
liver stages, referred to as hypnozoites, that occurs several weeks to years after 
the first infection by bite of a mosquito (Krotoski, 1985). Clearance of these 
dormant liver stages requires the use of the 8-aminoquinoline drug primaquine 
because most drugs effective against blood-stages of P. vivax have no effect on 
hypnozoites More recently there have also been a rise in the number of severe 
cases of vivax malaria (Alexandre et al., 2010; Kochar et al., 2009), widespread 
drug resistance (Baird, Basri, et al., 1991; Price et al., 2014; Rieckmann et al., 
1989) including strains with low sensitivity to primaquine (Baird & Hoffman, 
2004). There is an urgent need to develop a vaccine to control and prevent vivax 
malaria.  
Naturally acquired immunity to malaria is largely associated with antibody 
response to blood stage infection, specifically against proteins involved in the 
invasion of erythrocytes (Marsh & Kinyanjui, 2006; Yazdani et al., 2006). 
Consistent with this view, many of the parasite antigens considered as targets of 
this protective immunity display the characteristic patterns of polymorphisms of 
residues under selective immune pressure.  Duffy binding protein is a prime 
example of such blood-stage target, exhibiting extensive variation in residues of 
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its functional ligand domain. Plasmodium vivax almost exclusively invades Duffy 
positive red blood cells, although recently there have been a few unexplained 
sporadic cases of vivax among Duffy negative individuals (Cavasini et al., 2007; 
Menard et al., 2013; Ryan et al., 2006). The exclusivity of P. vivax is attributed to 
the Duffy binding protein on the merozoite which binds irreversibly to its cognate 
receptor, the Duffy antigen receptor for chemokines (DARC), on the erythrocyte, 
forming the junction critical for invasion (Adams et al., 1990; Adams et al., 1992; 
Chitnis et al., 1996; Miller et al., 1976; Miller et al., 1975; Wertheimer & Barnwell, 
1989). Hence DBP region II (DBPII), essential for binding to DARC (Chitnis & 
Miller, 1994; Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et al., 2004), is a 
prime asexual blood stage vaccine candidate.  
As a result of the highly polymorphic nature of DBPII (Ampudia et al., 
1996; Tsuboi et al., 1994; Xainli et al., 2000), naturally acquired immunity is 
strain specific (J. L. Cole-Tobian et al., 2009; McHenry et al., 2011; Ntumngia et 
al., 2012b; VanBuskirk, Cole-Tobian, et al., 2004). In pre-clinical mouse studies, 
a multi-allele DBPII vaccine was more immunogenic and produced a stronger 
strain neutralizing response than a single-allele vaccine (Ntumngia et al., 2013). 
To over come the inherent strain specificity of the immune response to DBPII, a 
novel synthetic DBPII antigen called DEKnull, was designed. This was derived by 
mutating the residues of an immunodominant polymorphic B-cell epitope within 
DBPII, referred to as the “DEK” epitope. Compared to its natural parent allele 
Sal1, DEKnull vaccine was less immunogenic but produced an immune response 
that was similar to a single natural allele vaccine (Ntumngia & Adams, 2012; 
	   87 
Ntumngia et al., 2013), suggesting that the immune response was to one or more 
conserved epitopes. These studies prove that identifying epitopes on DBPII will 
be very helpful in designing a vaccine that produces strain-transcending 
immunity.  
Almost since the discovery of phage display as a tool, epitope mapping 
studies have been conducted to help design a vaccine against malaria (de la 
Cruz, Lal, & McCutchan, 1988; Parmley & Smith, 1989). Although an epitope 
may only be a few residues, many epitopes are composed of discontinuous 
residues that come together to create a 3D conformation-dependent epitope of 
the protein that is crucial for optimal antibody binding, rendering gene fragment 
libraries and random peptide libraries less than ideal to elucidate all critical 
residues that make up an epitope.  Nonetheless as demonstrated by the studies 
presented in Chapter 2 it is possible for even linear synthetic peptides to induce 
some level of inhibition to a native protein dependent on its 3D structure for 
function.  Therefore, providing some additional structural support via a protein 
scaffold for presentation of DBPII epitopes may enhance immunogenicity and 
functional efficacy of vaccine-elicited antibodies to inhibit DBP function.  
Non-immunoglobulin affinity protein scaffolds is a growing field marked 
with varied polypeptide folds that are highly stable, easily produced and dotted 
with various residue positions that can be randomized. One type of helical 
scaffold library, Affibodies, engineered from Staphylococcal protein A (Fig 3.1), is 
similar to Monobodies, a bête scaffold engineered from human fibronectin. 
Affibodies have been used to select for receptors or enzymes with affinities 
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(dissociation constant KD) in the 10µM to 3nM range (Gunneriusson et al., 1999; 
Hansson et al., 1999; Nord et al., 1997; Nord et al., 2001). Here we propose that 
these protein scaffold libraries could also be used to identify conformational 
epitopes reactive with inhibitory anti-DBPII mAbs.   
Crystallography studies reveal that DBPII is largely alpha-helical and may be 
assigned into three sub-domains delineated by six disulphide bonds (Batchelor et 
al., 2011). While sub-domain 1 of DBPII is made up of an antiparallel beta-
hairpin, sub-domains 2 and 3 are seen as distinct bundles of three alpha-helixes. 
Inhibitory human and murine mAbs have been shown to bind to sub-domain 2 
(Chootong et al., 2010) and sub-domain 3 (presented in Chapter 2), respectively. 
This study has sought to use an alternate alphahelical scaffold as a tool for 
isolation of DBPII structural epitopes.  An affibody library (Nord et al., 1997), 
representing a randomized, three alpha-helical bundle structure, was used to 
screen for conformation-dependent epitope mimics reactive with the murine anti-
DBPII mAbs. The purpose of the study was to determine if a rigid scaffold, such 
as the Affibody, could provide an alternate phage system for identifying and 
characterizing mimotopes of DBPII. 
 
MATERIALS AND METHODS 
Biotinylation of antibodies  
Murine mAbs 3D10, 3C9, 2D10 and 1DK of IgG isotype IgG1 and κ light 
chain were used. Biotinylation of target mAbs 3D10, 3C9 and 2D10 were carried 
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out using N-Hydroxysuccinimide (NHS) activated biotin with EZ-Link Sulfo-NHS-
LC-Biotin (Thermo Scientific 21327) following manufacturer’s instructions at 20 
molar fold excess biotin followed by dialysis. The level of biotinylation was 
determined by evaluation of binding to streptavidin-coated beads as seen on a 
10% SDS PAGE gel. Monoclonal antibody 1DK was left unbiotinylated and was 
used as a control.  
 
Affiibody selections 
The Affibody library (naïve library pAffi100-tryp designed by PÅ 2013) on 
the phagemid vector pKN1 (Nord, Nilsson, Nilsson, Uhlen, & Nygren, 1995) was 
grown in E. coli strain RR1ΔM15 (supE) (Ruther, 1982). Phage stocks were 
prepared using M13K07 helper phage. Washed neutravidin magnetic particles 
(Spherotech NVM-20-5) and Streptavidin beads (Invitrogen Dynabeads M-280) 
were incubated with excess biotinylated target mAbs for 1 h at room temperature 
with end-over-end rotation. The beads were then washed and stored at 4°C to be 
used alternatively through the round of panning. The panning procedure was 
carried out as described previously (Hansson et al., 1999; Nord et al., 1997) over 
four rounds with an increasing number of PBST (PBS with 0.05% Tween 20) 
washes (2, 5 and 6 more washes). Briefly, Affibody library of approximately 1011 
phage forming units in 500 µl was first subjected to negative pre-selection by 
incubation with neutravidin magnetic particles, 100 nM mAb1DK and 3% BSA for 
1 h on a rotator at room temperature. Unbound phage particles were then 
transferred for selection to target mAb on neutravidin magnetic particles, by 
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incubating on a rotator for 1 h at room temperature and then washed with PBST. 
Bound phage particles were eluted for 10 min with 500 µl of Glycine HCl, pH 2.7 
and immediately neutralized with 50 µl of TrisHCl, pH 9. The eluted phage was 
used to infect log phase RR1ΔM15 E. coli grown in 100 ml of Tryptic Soy Broth 
supplemented with 20% Glucose for 1 h at 37°C. Helper phage was added and 
incubated for 30 min at 37°C. The cells were pelleted and resuspended in 100 ml 
Tryptic Soy Broth Yeast Extract media containing with 0.1M IPTG, 100 µg/ml 
Ampicillin and 25 µg/ml Kanamycin, grown over night at 30°C with shaking. 
Phage particles were isolated using standard polyethylene glycol precipitation 
and the concentration was determined for the subsequent round of selection. 
 
ELISA screen of clones 
Phage clones from the eluate of round four panning were randomly picked 
and grown in 1 ml of Tryptic Soy Broth Yeast Extract media with 0.1M IPTG and 
100 µg/ml Ampicillin for 24 h at 30°C with shaking. Affibody present in the 
periplasmic membrane was extracted in PBST by repeated freeze-thaw cycles. 
ELISA plates were coated with 5 µg/ml of human serum albumin over night at 
4°C. PBST wash was followed by incubation of 100 µl of periplasmic content 
from each clone for 2 h at room temperature. Unbound periplasmic content was 
then washed off with PBST and 5 µg/ml of the primary mAb in 0.5% casein or 1% 
milk in PBST was added and incubated for 1 h at room temperature. This was 
followed by addition of secondary goat anti-mouse horseradish peroxidase 
conjugated antibody at 1:5000 dilution. Absorbance was read at 450nm.   
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Sequencing 
Colonies from round 4 of panning that produced a strong response by 
ELISA was sequenced. Colony PCR was carried out using primers 5’-
CACACAGGAAACAGCTATGACCAT-3’ and 5’-
CTATCAGTGCTTTTACACCTTCAACAG-3’. The PCR product was purified by 
ethanol precipitation and sequenced using BigDye Terminators 3.1 (Applied 
Biosystems) with cycle sequencing DNA methodology on a MegaBACETM 1000 
instrument (Amersham Biosciences). 
 
RESULTS 
Anti-DBPII murine mAbs 3C9, 2D10 and 3D10 were biotinylated and then 
affinity selected on neutravidin and streptavidin beads (Fig 3.2). As a control, a 
biotinylated human IgG mAbs was also allowed to bind to both kinds of beads. All 
mAbs bound well to each of the beads and excess is seen in the supernatant, 
suggesting that the beads were saturated.  Gels show two distinct bands for the 
heavy chain and the light chain. A third bovine serum albumin (BSA) band is 
seen in wells loaded with streptavidin beads as these beads were stored with 
BSA (Fig 3.2 B). These purified avidin conjugated-mAbs were used to capture 
phage displayed affibodies that have an affinity to the mAb. 
After four rounds of panning of the Affibody library on each monoclonal 
antibody we analyzed individual clones. Periplasmic extract from 96 clones from 
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round four for each mAb panned on, were screened for affinity to the target mAb 
and another mAb as a control for background (Fig 3.3). In order to account for 
non-specific binding, only clones that showed greater affinity to the target mAb 
(in black) compared to the control mAb (in gray) were considered for sequencing. 
Conformation-independent mAb 3D10 (Fig 3.3 A) has fewer clones that bound 
with affinity compared to conformation dependent mAb 3C9 (Fig 3.3 B) and mAb 
2D10 (Fig 3.3 C). DNA sequencing results form clones identified show that there 
are few clones that have picked up variant residues at the central Isoleucine 31 
residue (Fig 3.4, 3.5 and 3.6).  
 
DISCUSSION 
The DBPII is primarily composed of alpha-helices with an antiparallel beta-
hairpin near the N-terminus (Batchelor et al., 2011). This elongate boomerang 
shaped structure can be further divided into sub-domains delineated by 
disulphide bonds. Human inhibitory mAb epitopes have been mapped to the 
three helix bundle structure of sub-domain 2 (Chootong et al., 2010) while 
inhibitory murine mAbs bind to sub-domain 3 (presented in chapter 2) which is 
also made up of a three helix bundle. As a proof of concept experiment, the use 
of helical scaffold Affibody library to identify epitopes of murine mAbs that vary in 
both binding inhibition of DBPII-erythrocyte and conformation dependents of 
DBPII. Similar anti-idiotypic studies on HIV-1 Env-specific antibodies were 
carried out using the 10th domain of human fibronectin (FNfn10) as an 
engineered scaffold to generate Monobodies that mimicked both linear epitopes 
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(mAbs 2F5 and 4E10) and conformational epitopes (b12 and VRCO1) (Sullivan 
et al., 2013). 
Staphylococcal protein A is widely used in antibody purification and 
detection (Uhlen, Forsberg, Moks, Hartmanis, & Nilsson, 1992). Protein A has 
repetitive structures consisting of small individually folded, highly stable alpha-
helical domains that specifically binds to the Fc region of IgG from different 
species (Moks et al., 1986; Samuelsson, Jonasson, Viklund, Nilsson, & Uhlen, 
1996; Samuelsson, Moks, Nilsson, & Uhlen, 1994; Stahl & Nygren, 1997). The 
58-residue B domain, engineered with a single amino acid mutation for increased 
chemical stability (Protein Z), was further determined to be tolerant to multiple 
random amino acid substitutions at the Fc binding surface (Cedergren, 
Andersson, Jansson, Uhlen, & Nilsson, 1993; Jendeberg et al., 1995; Nilsson et 
al., 1987; Nord et al., 1995) giving rise to the Z domain libraries (Nord et al., 
1997) later to be called Affibodies library (Hansson et al., 1999). Using M13 
phage these libraries could be displayed as a fusion protein and be used for 
affinity selection or biopanning (Nord et al., 1995). This combinatorial library was 
first randomized at 13 residues distributed across helix 1 and 2 (Fig 3.1). Initially 
it was thought that Isoleucine at position 31 on helix 2 is important for helix-helix 
packing and was not included as a residue to be randomized. However, it was 
later determined that because of its central position on the randomized region, 
substitution of this residue may provide useful information about binding sites 
that may use a variant residue at the central position of Ile31. 
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Selection of Affibodies showing anti-idiotypic characteristic has been well 
established (Eklund, Axelsson, Uhlen, & Nygren, 2002). Crystal structure of a 
complex of an in vitro selected Affibody bound to protein Z reveals similar 
properties to antibody-antigen complex (Hogbom, Eklund, Nygren, & Nordlund, 
2003). This study of an artificially evolved protein –protein complex of two 
globular proteins is similar to Ab-antigen complex marked by the complex burring 
at 1,665 Å2 and the nine H bonds. However the rigidity of the three helix structure 
compared to the loops that form the complementary determining region of Abs 
and the lack of a buried water molecule in the Affibody complex, suggests that 
the interaction is more complementary than the typical Ab-antigen complexes. 
Hence these studies show that the Affibody can form a complex with a protein 
similar to that of an antibody, interacting with similar residues, and that the 
Affibody – protein complex can be selected for in vitro. We use these findings as 
the bases to study the interaction of anti-DBP antibodies to the helical structure 
of DBPII using the Affibody library. 
Conformation dependent anti DBPII mAbs 3C9 (IC50 = 0.19 and 0.16 
µg/ml) and 2D10 (0.35 and 0.18 µg/ml) showed differential inhibitory responses 
to the DBPII alleles 7.18 and Sal1, respectively, expressed on COS7 cells 
(Ntumngia et al., 2012b). This suggests that either these antibodies might be 
binding to different epitopes within the different alleles or that the polymorphisms 
in DBPII sub-domain 3 has significant influence on functional activity of these 
antibodies. While both mAbs 2D10 and 3C9 were produced in mice immunized 
with DBPII 7.18 allele, 2D10 showed almost 2 fold increase in inhibition 
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compared to Sal1 allele. Conformation independent non-inhibitory mAb 3D10 
binds to recombinant refolded DBPII with significantly greater affinity (~5 fold) 
than denatured rDBPII. 
The Affibody library used in this study not only had the original 13 
randomized residues, on helix 1 and 2, involved in the Fc-binding activity but also 
Ile31 was randomized to include Asp, His, Lys and Tyr, each at 10%, at position 
31. It is interesting to note that several of the Affibody clones that bound well to 
the target antibody had one of these substitutes for Isoleucine at position 31. 
Amino acid sequence alignment of 3C9 epitope on DBPII (presented in Chapter 
2) along with round 4 clones from panning on mAb 3C9 suggests that a good 
portion of non-randomized region of the Affibody helix is conserved in the 3C9 
epitope. Hence making it increasingly difficult to identify residues of importance. 
MAb 2D10 also seems to bind a region very close to the 3C9 epitope on DBPII 
(presented in Chapter 2) and clones from round 4 panning also align well to the 
C terminal region of DBPII subdomain3.  
Competition ELISAs and site directed mutagenesis studies need to be 
carried out to determine essential residues. More in-depth structural alignment 
studies of DBPII and Affibody clones that were identified may be required to draw 
conclusions on the residues that are most essential for the mAbs 3C9 and mAb 
2D10. Another round of panning may also help identify clones that bind with 
affinity affinities KD in the µM to nM range to determine essential residues that 
make up the helical structure of the epitope.  
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TABLES AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Affibody crystal structure and sequence. Crystal structure of an 
Affibody (pdb1h0t) with randomized regions shown as sticks in peach and Ile31 
in green (Wahlberg et al., 2003).  
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Figure 3.2: SDS-PAGE gel of biotinylated antibodies on neutravidin and 
streptavidin beads. Biotinylated antibodies incubated with Neutravidin beads (A) 
and streptavidin beads (B) were run on 10% reducing gel as antibody bound 
beads (b) and supernatant (s) along with protein ladder (L). Distinct bands for 
heavy (<66kDa) and light chains (30kDa) can be seen on both gels. A third BSA 
band (66kDa) is seen in wells with streptavidin beads as BSA was in the storage 
buffer. 
 
 
Figure 3.3: ELISA on clones from Round 4 panning on murine mAbs. Affibody 
from periplasmic content of clones from the last round of panning were tested for 
affinity to its respective antibody as well as a control antibody. Clones that 
showed higher binding to mAb 3D10 (in A), mAb 3C9 (in B) and mAb 2D10 (in C) 
compared to the control antibody were studied further. 
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Figure 3.4: Amino acid sequence alignments for Round 4 panning on mAb 3C9. 
Clones from round 4 were aligned to 3C9 epitope on DBPII. Highlighted in gray 
are the amino acid residues that were conserved in the Affibody helix. 
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Figure 3.5: Amino acid sequence alignments for Round 4 panning on mAb 2D10. 
Clones from round 4 were aligned. Highlighted in gray are the amino acid 
residues that were conserved in the Affibody helix. 
 
 
 
Figure 3.6: Amino acid sequence alignments for Round 4 panning on mAb 3D10. 
Clones from round 4 were aligned. Highlighted in gray are the amino acid 
residues that were conserved in the Affibody helix. 
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CHAPTER FOUR: 
SUMMARY 
 
Malaria causes a huge burden of disease globally, with about 3.3 billion people at 
risk of being infected ("World Malaria Report 2014," 2014). Plasmodium vivax is 
the second most common cause of human malaria. Plasmodium vivax 
preferentially invades reticulocytes (Butcher et al., 1973; Mons, 1990) with Duffy 
blood group antigen otherwise known as Duffy antigen receptor for chemokines 
(DARC) (Miller et al., 1976). Plasmodium vivax Duffy binding protein (DBP), 
expressed on the merozoite surface just in time for invasion, binds to its cognate 
receptor DARC on the reticulocyte surface forming an irreversible junction, 
critical for merozoite invasion (Adams et al., 1990; Adams et al., 1992; Chitnis et 
al., 1996; Miller et al., 1976; Miller et al., 1975; Wertheimer & Barnwell, 1989). 
Plasmodium vivax almost exclusively use DARC as a receptor to invade 
reticulocytes, however, more recently, there have been a few P. vivax cases 
reported among Duffy negative individuals (Cavasini et al., 2007; Menard et al., 
2013; Ryan et al., 2006), this is rare and an alternate receptor-ligand invasion 
pathway is unknown. Hence PvDBP remains a prime candidate for vaccine-
induced immunity against asexual blood stage P. vivax infection. 
The cysteine rich DBP region II (DBPII) that constitutes the principal 
determinants for receptor recognition (Adams et al., 1992; Chitnis & Miller, 1994; 
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Ranjan & Chitnis, 1999; VanBuskirk, Sevova, et al., 2004) is highly polymorphic 
(Ampudia et al., 1996; Tsuboi et al., 1994; Xainli et al., 2000), in a pattern 
consistent with high immune selection pressure on DBPII (Baum et al., 2003; 
Baum et al., 2002). Residues critical for receptor recognition are flanked by 
polymorphic residues that are not important for binding to the receptor (Batchelor 
et al., 2011; VanBuskirk, Sevova, et al., 2004; Xainli et al., 2000). These 
polymorphisms are a challenge to developing a vaccine since they contribute to 
anti-DBP strain-specific in naturally acquired immunity (J. L. Cole-Tobian et al., 
2009; McHenry et al., 2011; Ntumngia et al., 2012b; VanBuskirk, Cole-Tobian, et 
al., 2004).  
To overcome the inherent tendency for anti-DBP immune responses to be 
strain specific, a novel synthetic DBPII called DEKnull was produced. The B-cell 
immunodominat and polymorphic residues of the DEK epitope (Chootong et al., 
2010) were mutated in DEKnull. Compared to the natural parent allele Sal1, 
DEKnull vaccine was less immunogenic but it produced an immune response, in 
mice, that was similar to a single natural allele vaccine (Ntumngia & Adams, 
2012; Ntumngia et al., 2013). These studies prove that identifying conserved 
protective epitopes on DBP will be very helpful in designing a vaccine that 
produces a broadly neutralizing, strain-transcending immunity.  
Previously, we generated and immunologically characterized a panel of 
anti-DBPII murine mAbs. Some of these mAbs were broadly inhibitory like mAbs 
3C9, 2D10, 2C6 and 2H2 while mAb 3D10 was a poor inhibitor to DBPII-
erythrocyte binding in a standard in vitro COS 7 cell assay (Ntumngia et al., 
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2012b). With the exception of mAb 3D10, all the mAbs specifically recognized 
only conformational dependent epitopes on recombinant DBPII. 
Phage display has been a useful tool for epitope mapping with the 
advantages of rapidly producing refolded protein, fused to phage coat; forming a 
traceable link back to the genotype (Smith, 1985; Wilson & Finlay, 1998). 
Crystallography studies reveal that DBPII is largely alpha-helical and may be 
assigned into three sub-domains delineated by six disulphide bonds (Batchelor et 
al., 2011). Using phage display we have previously shown that, each of the sub-
domains or natural combinations of the sub-domains of DBPII have varying 
patterns of affinity to these mAbs (Siddiqui et al., 2012). These data suggest that 
identifying the epitopes of these inhibitory and non-inhibitory mAbs will help 
design a strain-transcending subunit vaccine.  
In this study, we further map the epitopes of these anti-DBPII mAbs by 
screening DBPII (Sal1 and 7.18) gene fragment libraries using phage display. 
After three to four rounds of affinity selection to each of the mAbs, DNA 
sequence from bacterial clones of the last round the minimal reactive peptide 
fragments were identified. Interestingly, a region on subdomain 3 was the epitope 
on DBPII for broadly inhibitory mAbs 3C9, 2D10, 2C6 and 2H2 while non-
inhibitory mAb 3D10 epitope was on subdomain 1.  
Further, panning using a random peptide library or a random scaffold 
library and site directed mutagenesis was used to determine the relative 
importance of residues within the identified epitope region. Panning using a 
random 20-mer peptide library to define the minimal epitope of conformation 
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independent mAb 3D10 identified the ‘YKR’ region common between the DPBII 
epitope and round 3 mimotopes. A random scaffold library was also used to 
study the epitopes of conformation dependent mAbs 3C9 and 2D10. Further 
analysis of structural and amino acid sequence alignments needs to be carried 
out.  
Site directed mutagenesis studies reveled that multiple mutations to 
residues Y445A, V446A, F530A and F535A reduced binding to both mAb 3C9 
and mAb 2D10 suggesting that there is some synergistic interaction of these 
aromatic residues that make up the 3C9 and 2D10 binding pocket on. E538 
seems to have polar interactions with F535 in the epitope and Y445 in the 
neighboring helix, which seems to be more important for binding of mAb 3C9 
than mAb 2D10. However, V446 seems to interact with G442, which is more 
important for binding of mAb 2D10 than mAb 3C9. 
Peptides identified from the gene fragment library panning and random 
peptide panning were conjugated to carrier protein KLH and used to immunize 
mice. All groups of mice produced an immune response to the respective 
peptide, determined by ELISA. However, only 3C9 epitope peptide elicited 
antibodies that recognized rDBPII. Using the standard in vitro COS7 assay a 
concentration-dependent inhibition of DBPII-erythrocyte binding was observed 
using anti-3C9 epitope sera. Binding inhibition curves for alleles 7.18 and AH 
showed no significant difference compared to Sal1. These results show promise 
that the 3C9 linear peptide may be inherently able to assume its 3D conformation 
as on native DBP and it is a target of binding inhibitory antibody.  
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These results from this study contribute to our understanding of the 
specific targets for vaccine-elicited protective immunity. In particular, this study 
demonstrates an approach that may be successful in boosting antibody 
responses targeted against conserved protective epitopes, with functional 
inhibition against broader allelic variants and diverse P. vivax strains. 
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